Document:

Exhibit 10.2

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES
ACT OF 1933, AS AMENDED.

 

[*] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF
A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
COMMISSION.

Execution Version

 

MAY 20, 2010

 

BioSynthema Inc. and

 

Advanced Accelerator Applications, S.A.

 

SALE AND PURCHASE AGREEMENT

 

FOR THE ENTIRE ISSUED SHARE CAPITALOF

 

BIOSYNTHEMA INC.

 

 

 

 

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	 	 	Page
	1.	Definitions and Interpretation	1
	2.	Sale and Purchase	12
	3.	Initial Cash Payment; Initial Shares	12
	4.	Contingent Cash Consideration; Contingent Shares	13
	5.	Royalty Payments and Obligations	15
	6.	Conditions	18
	7.	Conduct of Business Before Completion	19
	8.	Completion	20
	9.	Representations and Warranties; Limitations; Cure Period	20
	10.	Survival Following Completion	22
	11.	Remedies and Waivers	22
	12.	Assignment	23
	13.	Entire Agreement; Amendment	23
	14.	Notices	23
	15.	Confidentiality	24
	16.	Costs and Expenses	26
	17.	Counterparts	27
	18.	Termination	27
	19.	Dispute Resolution	28
	20.	Currency Conversion	28
	21.	Severability	28
	22.	Choice of Governing Law; Venue; Service of Process and Judgments	28
	23.	Press Announcements	29
	24.	Further Assurances; Mutual Drafting	29

 

	 	Schedule 1 - Shareholders
	 	Schedule 2 - Conditions to Completion
	 	Schedule 3 - Representations and Warranties
	 	Schedule 4 - Company Subsidiaries
	 	Schedule 5 - Restricted Actions
	 	Schedule 6 - Indemnification Obligations
	 	Schedule 7 - Accounts as of December 31, 2009·

 

    	i

    	 

    

 

THIS SALE AND PURCHASE AGREEMENT
(the "Agreement") is made as of this 20th day of May, 2010

 

BY AND AMONG:

 

		1.	The several persons whose names are set out in Schedule
1 (the "Shareholders"); and

 

		2.	Advanced Accelerator Applications, S.A., a limited company (societe anonyme) registered under the
laws of France, and whose corporate headquarters is at 20 rue Diesel, 01630 Saint-Genis-Pouilly, France (the "Purchaser");
and

 

		3.	BioSynthema Inc., a company incorporated under the laws of Missouri, United States of America,
whose corporate headquarters is at 4041 Forest Park Boulevard, St. Louis, Missouri 63108, United States of America (the "Company,"
the Shareholders, the Purchaser and the Company may be referred to herein individually as a "Party" or collectively as
the "Parties").

 

WHEREAS:

 

The Shareholders have each agreed
to transfer and sell the Company Shares owned by them and the Purchaser has agreed to purchase and pay for all the Company Shares,
in each case on the terms and subject to the conditions of this Agreement.

 

NOW IT IS HEREBY AGREED as
follows:

 

1.DEFINITIONS AND INTERPRETATION

 

1.1              In this Agreement,
the schedules and the Disclosure Letter, the following terms shall be defined as set forth below:

 

"Accounts" means
the consolidated unaudited financial statements of the Company (comprising a balance sheet, consolidated statement of profit and
loss and statement of cash flows for the fiscal year ended on 31 December 2009 with the notes thereto).

 

"Accounts Date"
means December 31,2009.

 

"Accounts Receivable"
has the meaning ascribed thereto in Schedule 3, Part A, and Section 22.

 

"Action" has the
meaning ascribed thereto in Schedule 3, Part A, and Section 5.1.

 

"Affiliate" means, (i) in respect of any person including an individual, a person that directly,
or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, the person specified,
where "control" means the possession,

 

    	- 1 -

    	 

    

 

directly or indirectly, of the power
to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities,
by agreement, as trustee or executor, or otherwise, and (ii) in respect of any individual, his or her grandparents and all descendants
of those grandparents and (in each case) their spouses or a trust of which any of them is a beneficiary.

 

"Aggregate Consideration"
has the meaning ascribed thereto in Section 2.1.

 

"Agreement" has the meaning
set forth in the first sentence hereof.

 

"Authorizations"
has the meaning ascribed thereto in Schedule 3, Part A, Section 16.

 

"Benchmark Value"
means € 2.50 per Purchaser Share.

 

"Breaching Party"
has the meaning ascribed thereto in Section 9.4.

 

"Breaching Shareholder"
has the meaning ascribed thereto in Schedule 6, Section 2.1.

 

"Business" means
the businesses and activities of the Company and Company Subsidiaries (including businesses as carried on at the date of this Agreement
or at any time prior to Completion).

 

"Business Day" means
a day (other than a Saturday or a Sunday) on which financial institutions are open for business in London, England and New York
City, New York, United States of America.

 

"Claim Notice" has the meaning
ascribed thereto in Section 2.1 of Schedule 6. "Clinical Trials Target" has the meaning ascribed thereto in Section
4.1. "Code" means the Internal Revenue Code of 1986, as amended.

 

"Combination
Product" means a Product or Substitute Product sold in a finished dosage form containing a Product or Substitute Product
in combination with one or more other products or ingredients which are not Products or Substitute Products.

 

"Common Stock" means the common
stock, par value $0.10 of the Company

 

"Company" has the meaning
ascribed thereto in the third recital.

 

"Company Benefit Plans"
has the meaning ascribed thereto in Schedule 3, Part A, Section 7.1.

 

"Company ERISA Affiliate"
has the meaning ascribed thereto in Schedule 3, Part A, and Section 7.1

 

    	- 2 -

    	 

    

 

"Company Intellectual Property"
has the meaning ascribed thereto in Schedule 3, Part A, and Section 21.

 

"Company Legal Counsel" means
Palank & Associates, LLC.

 

"Company Material Adverse Effect"
means such circumstances, event or change that has had a material adverse effect on the business, operations or financial condition
of the Company, but shall not include facts, circumstances, event or changes (i) generally affecting the economy or the financial,
debt, credit or securities markets, in the United States or elsewhere, (ii) resulting from political conditions or developments
in general, (iii) reflecting or resulting from changes or proposed changes in any Law (or interpretations thereof), (iv) resulting
from the taking of any action contemplated by this Agreement and the other agreements contemplated hereby, or (v) any facts, circumstances,
events or changes that are cured by the Shareholders before the Completion Date.

 

"Company Material Contract"
has the meaning ascribed thereto in Schedule 3, Part A, Section 20.

 

"Company Obligations" means
(i) the loans from Stichting BWE to the Company in the amounts of $300,000 and €250,000, respectively, as each was amended
May 1, 2010 and (ii) the $250,000 payable to Mallinckrodt Inc. on or before September 11, 2010, each as further described in the
Disclosure Letter.

 

"Company Organization Documents"
has the meaning ascribed thereto in Schedule 3, Part A, Section 1.

 

"Company Real Property"
has the meaning ascribed thereto in Schedule 3, Part A, and Section 9.1.

 

"Company Shares" means the
5,390,033 shares of Common Stock issued and outstanding as of the date of this Agreement.

 

"Company Subsidiary" means
any Subsidiary of the Company.

 

"Company Subsidiary Organization Documents"
has the meaning ascribed thereto in Schedule 3 Sections 1.

 

"Completion" means the completion
of the sale and purchase of the Company Shares pursuant to the terms of this Agreement.

 

"Completion Date" means the
date of Completion or such other date as the Purchaser and the Majority Shareholders shall agree in writing to be the Completion
Date.

 

"Confidential Material" has
the meaning ascribed thereto in Section 15.1.

 

    	- 3 -

    	 

    

 

Contingent Consideration" means, collectively,
the Contingent Cash Consideration and the Contingent Shares.

 

"Contingent Cash Consideration"
has the meaning ascribed thereto in Section 2.1.

 

"Contingent Shares"
has the meaning ascribed thereto in Section 2.1.

 

"Damages" has the
meaning ascribed thereto in Section 2.1 of Schedule 6.

 

"Deed of Adherence"
means a deed of adherence in a form satisfactory to the Purchaser, the Shareholders and the Company.

 

"Directors" mean Erion and
van Rossem.

  

"Disclosing Party" has the
meaning ascribed thereto in Section 15.1.

 

"Disclosure Letter" means
the letter having the same date as this Agreement from the Company to the Purchaser setting forth exceptions to Schedule 3.

 

"Earn Out" has the meaning
ascribed thereto in Section 5.8.

 

"EMEA” means the
European Medicines Agency (or any successor agency).

  

"Encumbrance" means any mortgage,
pledge, security interest, attachment, right of first refusal, option, proxy, voting trust, encumbrance, lien or charge of any
kind (including any conditional sale or other title retention agreement or lease in the nature thereof), restrictions (whether
on voting, sale, transfer, disposition or otherwise), any subordination arrangement in favor of another person, any filing or agreement
to file a financing statement as debtor under the Uniform Commercial Code or any similar statute.

 

"End Date" means
June 30, 2010, or such later date as may be agreed between the Purchaser, the Shareholders and the Company.

 

"Enforceability Exceptions"
has the meaning ascribed thereto in Schedule 3, Part A, and Section 2.1.

 

"Environmental Laws"
means any Law relating to (a) the protection, preservation or restoration of the environment (including air, water vapor, surface
water, groundwater, drinking water supply, surface land, subsurface land, plant and animal life or any other natural resource),
or (b) the exposure to, or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling,
production, release or disposal of Hazardous Substances, in each case as in effect at the date hereof.

 

"Erion" means Jack
Erion, an individual having an address of 379 Woodmere Nook Court, St. Charles, Missouri 63303.

 

    	- 4 -

    	 

    

 

"ERISA" has
the meaning ascribed thereto in Schedule 3, Part A, and Section 7.1.

 

"Executory Period"
has the meaning ascribed thereto in Schedule 5, Section 1.

 

"FDA" has the meaning
ascribed thereto in Schedule 3, Part A, and Section 16.

 

"Fifth Year" has
the meaning ascribed thereto in Schedule 6, Section 2.2.

 

"First Commercial Sale"
means the initial ‘commercial sale’ of the Product (or the Substitute Product) that has obtained marketing authorization
by either the FDA and/or EMEA.

 

"First Year" has the meaning
ascribed thereto in Schedule 6, Section 2.2.

 

"Fourth Year" has the meaning
ascribed thereto in Schedule 6, Section 2.2.

 

"GEP-NET" means Gastro-entero-pancreatic
Neuroendocrine Tumor.

 

"Gross Profit Margin"
shall mean, for any fiscal year of the Company, the quotient of (x) Net Sales less the sum of (i) direct production costs plus
(ii) distribution payments to any distributor or agent divided by (y) Net Sales.

 

"Governmental Entity" any
nation or government, any state or other political subdivision thereof, any entity, authority or body exercising executive, legislative,
judicial, regulatory or administrative functions of or pertaining to government, including any governmental or regulatory authority,
agency, department, board, commission, administration or instrumentality, any court, tribunal or arbitrator or any self-regulatory
organization.

 

"Hazardous
Substance" means any substance listed, defined, designated or classified as hazardous, toxic, radioactive or
dangerous or as a pollutant or contaminant under any environmental Law. Hazardous Substances include any substance to which
exposure is regulated by any Governmental Entity or any Environmental Law, including (a) petroleum or any derivative or
byproduct thereof, toxic mold, asbestos or asbestos containing material or polychlorinated biphenyls and (b) all substances
defined as Hazardous Substances, Oils, Pollutants or Contaminants in the National and Hazardous Substances Contingency Plan,
40 C.F.R. Section 300.5.

 

"Indebtedness" means (i)
all indebtedness for borrowed money or for the deferred purchase price of property or services (other than expenses and current
trade liabilities incurred in the ordinary course of business and payable in accordance with customary practices), (ii) any other
indebtedness that is evidenced by a note, bond, debenture, and credit agreement or similar instrument, (iii) all obligations under
financing leases, (iv) all obligations in respect of acceptances issued or created, (v) al1 1iabilities secured by an Encumbrance
on any property and (vi) all guarantee obligations.

 

    	- 5 -

    	 

    

  

"Indemnification Obligations"
has the meaning ascribed thereto in Section 1 of Schedule 6.

 

"Initial Cash Payment" has
the meaning ascribed thereto in Section 2.1.

 

"Initial Shares" has the meaning
ascribed thereto in Section 2.1.

 

"Intellectual Property" means
(i) United States, international and foreign patents and patent applications, including divisionals, continuations, continuations-in-part,
reissues, reexaminations and extensions thereof and counterparts claiming priority therefrom; utility models; invention disclosures;
and statutory invention registrations and certificates; (ii) United States and foreign registered, pending and unregistered trademarks,
service marks, trade dress, logos, trade names, corporate names and other source identifiers, domain names, Internet sites and
web pages; and registrations and applications for registration for any of the foregoing, together with all of the goodwill associated
therewith; (iii) United States and foreign registered and unregistered copyrights, and registrations and applications for registration
thereof; and copyrightable works; (iv) all inventions and design rights (whether patentable or unpatentable) and all categories
of trade secrets as defined in the Uniform Trade Secrets Act, including business, technical and financial information; and (v)
confidential and proprietary information, including know-how.

 

"Key Employees and Consultants"
means Jack L. Erion, President and CEO, and consultants: Jeanine Boesen through Boesen BV, Henk van Rossem and Mary Palank.

 

"Knowledge" or "Company
Knowledge" means the actual awareness of a given matter by the Key Employees and Consultants or any of them.

 

"Law" or "Laws"
means any foreign, federal, state or local Order, statute, law, rule, regulation, ordinance, principle of common law, constitution,
treaty enacted, or any writ, arbitration award, injunction, directive, judgment, or decree, promulgated, issued, enforced or entered
by any Governmental Entity.

 

"Licensed Intellectual Property"
has the meaning ascribed thereto in Schedule 3, Part A, and Section 21.

 

"Majority Shareholders" has
the meaning ascribed thereto in Section 18.1.

 

"Management Accounts" mean
the unaudited consolidated financial statements (comprising a balance sheet, consolidated statement of profit and loss, statement
of cash flows and statement of shareholders' equity) of the Company and Company Subsidiaries from the Accounts Date through the
Completion Date, each in the agreed form.

 

"Market Authorization Target"
has the meaning ascribed thereto in Section 4.1.

 

    	- 6 -

    	 

    

 

Market Value" means the
most recent price per Purchaser Share at which the Purchaser or the Purchaser's shareholders last sold its shares to bona fide
purchasers in bona fide stock sale transactions (including by way of subscription of increase of capital of the Company), excluding:
(i) any gift or other issuance for no or nominal value, (ii) transfer made following exercise of the pre-emption right provided
in the bylaws of the Purchaser, (iii) permitted transfers under the Shareholders' Agreement or (iv) any issuances, exercises or
purchases pursuant to any stock option, bonus or similar employee compensation plan of the Purchaser.

 

"Net Sales" means, with respect
to the commercial sale (as defined by the FDA or the EMEA) of the Product (or the Substitute Product, as the case may be), during
the prior completed fiscal year, the gross amount invoiced and effectively collected by or on behalf of the Purchaser (or the Company)
and their Subsidiaries (or Affiliates) for the Product (or Substitute Product) in bona fide, arm's-length transactions plus any
royalties received by Purchaser (or the Company) and their Subsidiaries from licensees or sublicensees from commercial sales of
the Product (or Substitute Product), less the following customary deductions, determined in accordance with US GAAP, to the extent
included in the gross invoiced commercial sales price of any Product or Substitute Product or otherwise directly paid or incurred
by the Purchaser, the Company or their Subsidiaries (and Affiliates) with respect to the commercial sale of such Product or Substitute
Product:

 

(i)           normal
and customary trade and quantity discounts actually allowed and properly taken directly with respect to commercial sales of the
Product or Substitute Product;

 

(ii)           amounts
actually repaid or credited by reason of defects, rejection recalls, returns, rebates and allowances of goods;

 

(iii)          charge-backs
and other amounts paid on commercial sales or dispensing of such Product;

 

(iv)         rebate
amounts payable resulting from governmental mandated rebate programs;

 

(v)          
tariffs, duties, excise, sales, value-added and other taxes (other than taxes based on income);

 

(vi)         
Customary cash discounts for timely payment; (vii) delayed ship order credits;

 

(viii)        discounts
pursuant to indigent patient programs and patient discount programs and coupon discounts;

 

(ix)           All freight, postage and
insurance included in the invoice price;

 

    	- 7 -

    	 

    

 

(x)         all
payments made to distributors, consultants or agents in connection with the sale of the Product (or Substitute Product);

 

(xi)        all
royalties (including royalties to Mallinckrodt) paid or other payments made to licensors in connection with the sale of the Product
(or Substitute Product).

 

Commercial sales
by the Purchaser and/or the Company to (i) any of their Affiliates, Subsidiaries, licensees or sublicensees or (ii) for clinical
trial use shall be disregarded for purposes of calculating Net Sales. Any of the items set forth above that would otherwise be
deducted from the invoice price in the calculation of the amount Net Sales but which are separately charged to third parties shall
not be deducted from the invoice price in the calculation of the amount Net Sales.

 

In the case of any commercial sale
or other disposal for value, such as barter or counter- trade, of the Product, or part thereof, other than in an arm's-length transaction
exclusively for money, the amount of Net Sales shall be calculated by the Company as above on the value of the non-cash consideration
received or the fair market price (if higher) of the Product or Substitute Product in the country of sale or disposal.

 

Net Sales from Combination Products
shall be determined in accordance with Section 5.3 by replacing the introduction to Section 5.3 as follows: "For the purpose
of determining the Royalty Payments with respect to sales of Combination Products" shall be replaced with "For the purpose
of determining Net Sales with respect to sales of Combination Products."

 

"Net Sales Target"
has the meaning ascribed to such term in Section 4.1.

 

"Officers" mean each of Erion and Palank.

 

"Order"
has the meaning ascribed thereto in Schedule 3, Part A, Section 5.1.

 

"Other Product" has the meaning ascribed
thereto in Section 5.3.

 

"Palank" means
Mary Palank, an individual having an address of 1034 S. Brentwood Blvd., Suite 1630, St. Louis, Missouri 63117, USA.

 

"Participating Member State"
means any member state of the European Union that adopts or has adopted the Euro as its lawful currency in accordance with legislation
of the European Union relating to Economic and Monetary Union.

 

"Party" or "Parties"
has the meaning ascribed thereto in the description of the parties to this Agreement on page 1 hereof.

 

"Plan" means that
certain Restricted Stock Bonus Plan of the Company, as approved December 29, 2004.

 

    	- 8 -

    	 

    

 

"Press Announcement"
means the press announcement to be issued by the Company and the Purchaser in the agreed form upon Completion.

 

"Proceedings" means any legal
proceedings or action arising out of or in connection with this Agreement or any other document referred to herein.

 

"Product" means, either: (i)
the 177-leutitum radiolabeled compound for radiotherapeutic or radiodiagnostic use in final dosage form and ready for infusion
into the patient, with "compound" meaning, the somatostatin peptide analogue, DOTAO-Tyr3-octreotate)o, r (ii) the vial
containing frozen or lyophilized material comprised of the compound plus other additives necessary for a commercially stable formulation
to which a 177-leutium solution is added to make the Product.

 

"Purchaser" has the meaning
ascribed thereto in the description of the parties to this Agreement on page 1 hereof.

 

"Purchaser General Indemnification
Claim" has the meaning ascribed thereto in Schedule 6, Section 2.2.

 

"Purchaser General Indemnification
Notice" has the meaning ascribed thereto in Schedule 6, Section 2.2.

 

"Purchaser Indemnified Party"
has the meaning ascribed thereto in Section 2.1 of Schedule 6.

 

"Purchaser Shares" means shares
of common stock of the Purchaser, nominal value of € 0.10 each;

 

"Purchaser Share" shall be
construed accordingly.

 

"Purchaser Survival Period"
has the meaning ascribed thereto in Section 1 of Schedule 6.

 

"Purchaser's Legal Counsel" means Ellenoff Grossman
& Schole LLP.

 

"Receiving Party"
has the meaning ascribed thereto in Section 15.1.

 

"Representatives" means, in
relation to a party, its respective Affiliates and the directors, officers, employees, agents, external legal advisers, accountants,
consultants and financial advisers of that party and/or of its respective Affiliates.

 

"Restricted Actions" means
the actions listed in Schedule 5.

 

"Royalty Payment" has the
meaning ascribed thereto in Section 5.1.

 

"Royalty Payment Objection Period"
has the meaning ascribed thereto in Section 5.5

 

"Royalty
Statement" has the meaning ascribed thereto in Section 5.5.

 

    	- 9 -

    	 

    

 

"Sale of the Company"
means, following the Completion of this Agreement, the acquisition, whether effected directly or indirectly or in one or a series
of transactions, by a third person not affiliated with the Purchaser of the capital stock or assets of the Company (other than
a sale, exchange or transfer to one or more entities where the Purchaser retains, directly or indirectly, at least a majority of
the beneficial interest in the voting stock of the entity or entities to which the assets were transferred), for an aggregate amount
exceeding the Aggregate Consideration (excluding any Royalty Payments) multiplied by three (3).

 

"Second Year" has the meaning
ascribed thereto in Schedule 6, Section 2.2.

 

"Securities Act" means the
Securities m Act of 1933, as amended.

 

"Shareholder Agreement"
means that certain Shareholders Agreement by and among all of the shareholders of the Purchaser effective as of March 1, 2009,
as amended on April 8, 2009.

 

"Shareholder Indemnification Cap"
has the meaning ascribed thereto in Schedule 6, Section 2.2(d).

 

"Shareholders" mean the holders
of Common Stock whose names and addresses are set out in Part 1 of Schedule 1.

 

"Side Letter" means that certain
side letter dated May 20 2010 pursuant to which van Rossem and Palank agree to certain non-competition and non-solicitation provisions.

  

"Subsidiary" or "Subsidiaries"
means any corporation, a majority of the outstanding voting power of which, or any partnership, joint venture, limited liability
company or other entity a majority of the total equity interests of which, is directly or indirectly (either alone or through or
together with any other subsidiary) owned by such specified person.

 

"Substitute Product" means
a molecule different from Lutate for treatment of GEP-NET (including carcinoid), for which the Purchaser or its Subsidiary or Affiliate
achieves Net Sales in lieu of the Product.

 

"Survival Period" has the
meaning ascribed thereto in Section 1 of Schedule 6.

 

"Surviving Provisions" means
Sections 5, 11, 14, 15, 22 and Schedule 6.

 

"Target" or "Targets"
means: (i) the Clinical Trials Target, (ii) the Market Authorization Target or (iii) the Net Sales Target, as applicable, and as
such terms are defined in Section 4.1.

 

"Tax" or "Taxes"
means any tax, custom, duty, governmental fee or other like assessment or charge of any kind whatsoever. Imposed by any Governmental
Entity (including any

 

    	- 10 -

    	 

    

 

federal, state, local, foreign or provincial
income, gross receipts, property, sales, use, net worth, premium, license, excise, franchise, employment, payroll, social security,
workers compensation, unemployment compensation, alternative or added minimum, ad valorem, transfer or excise tax) together with
any interest, addition or penalty imposed thereon.

 

"Tax Returns" has
the meaning ascribed thereto in Schedule 3, Part A, and Section 8.1.

 

"Tenant Leases" has
the meaning ascribed thereto in Schedule 3, Part A, and Section 9.1.

 

"Third Party Claim"
has the meaning ascribed thereto in Section 3 of Schedule 6.

 

"Third Year" has
the meaning ascribed thereto in Schedule 6, Section 2.2.

 

"Transaction Documents"
has the meaning ascribed thereto in Section 13.1.

 

"Uniform Commercial Code"
means the Uniform Commercial Code as in effect from time to time in the State of Missouri.

 

"US GAAP" means the
generally accepted accounting principles of the United States.

 

"van Rossem" means
Hendrik van Rossem, an individual having an address of Wihelminaplantsoen 13, 1601 LS Enkhuizen, The Netherlands.

 

"€" and "Euro"
means the single currency of the Participating Member States.

 

"$" and "US
Dollar" means the single currency of the United States of America.

 

1.2            In this Agreement, unless
otherwise specified:

 

(a)
         a reference to any Law shall be construed as a reference to the same as
it may have been, or may from time to time be, amended, modified or re-enacted except to the extent that any amendment or
modification made or coming into effect of any Law after the date of this Agreement would increase or alter the liability of
any of the Company, the Shareholders or the Purchaser under this Agreement; and

 

(b)          references
to a "company" shall be construed so as to include any company, corporation or other body corporate, wherever and however
incorporated or established; and

 

(c)          references
to a "person" shall be construed so as to include any individual, firm, company, Governmental Entity or any joint venture,
association or partnership (whether or not having separate legal personality); and

 

(d)          use of any gender inc1udesthe other gender; and

 

    	- 11 -

    	 

    

 

(e)         references to writing shall include any modes of reproducing
words in a legible and non transitory form; and

 

(f)          headings
to Sections and Schedules are for convenience only and do not affect the interpretation of this Agreement; and

 

(g)         the Recitals and Schedules
form part of this Agreement and shall have the same force and effect as if expressly set out in the body of this Agreement, and
any reference to this Agreement shall include the Recitals and the Schedules; and

 

(h)         references to "including"
shall be construed as "including without limitation."

 

2. SALE AND PURCHASE

 

2.1        At
Completion and subject to the terms and conditions set forth herein, each of the Shareholders shall irrevocably sell, free from
all Encumbrances and with full title guarantee, the Company Shares and the Purchaser shall purchase all of the Company Shares together
with all rights attached or accruing to them, for the following consideration (the "Aggregate Consideration"): (i) €
375,000 in cash (the "Initial Cash Payment"); (ii) that certain number of Purchaser Shares having an aggregate Market
Value of € 2,300,000 (the "Initial Shares"); (iii) up to € 1,125,000 in cash subject to the provisions of Section
4 (the "Contingent Cash Consideration"); (iv) that certain number of Purchaser Shares having up to an aggregate Market
Value of € 6,900,000 (the "Contingent Shares"); (v) the right to receive the Royalty Payment; and (vi) the assumption
of the Company Obligations; provided, however, the Contingent Consideration may be reduced in accordance with the Indemnification
Obligations.

 

2.2        With
effect from the Completion Date and by executing this Agreement, each of the Shareholders irrevocably waives any and all rights
over any of the Company Shares any of them ever had, now have or hereafter can, shall or may have, from the beginning of the world
to the end of time.

 

3. INITIAL CASH PAYMENT;
INITIAL SHARES

 

3.1        At Completion
and upon receipt of the duly endorsed certificates representing the Company Shares, the Purchaser (or its agent) shall: (i) distribute
the Initial Cash Payment and (ii) issue the Initial Shares, with each of (i) and (ii) being paid or issued, respectively, to the
Shareholders pro rata in accordance with their percentage ownership of the Company Shares set forth on Schedule 1; provided, however,
each Shareholder acknowledges that becoming a party to the Shareholder Agreement is an unwaivable condition precedent to receipt
of any Initial Shares due such Shareholder and that such Shareholder shall not be treated as a stockholder of Purchaser, shall
not appear on the records of the Purchaser as a shareholder and shall have no right, title or interest to

 

    	- 12 -

    	 

    

 

the Initial Shares until such
Shareholder has executed the Shareholder Agreement.The aggregate number of Initial Shares to be issued shall be 920,000.

 

3.2        Payment
of the Initial Cash Payment shall be made by wire transfer of funds in Euro to each of the Shareholders in accordance with Schedule
1.

 

3.3        A certificate
evidencing each Shareholder's pro rata portion of the Initial Shares shall be sent to the address set forth opposite each Shareholder's
name in Schedule 1 by Federal Express (or similar courier). Each of the Shareholders agrees that upon receipt of such certificate,
such Shareholder will not effect any sale, transfer, assignment, hypothecation, pledge or other Encumbrance of the Initial Shares,
unless such sale, transfer, assignment, hypothecation, pledge or other Encumbrance is made in accordance with (i) French securities
Laws (as evidenced by an opinion of counsel) or an applicable exemption therefrom and (ii) the Shareholder Agreement

 

4. CONTINGENT CASH CONSIDERATION;

CONTINGENT SHARES

 

4.1        At
such time that (i) clinical trials approved by the FDA and EMEA begin with respect to the Product (or Substitute Product) (the
"Clinical Trials Target"), (ii) marketing authorization is granted with respect to the Product (or Substitute Product)
by both the FDA and EMEA (the "Market Authorization Target") or (iii) aggregate Net Sales of the Product (or Substitute
Product) exceed € 10,000,000 in the aggregate (the "Net Sales Target"); then upon and subject to the satisfaction
of each such Target: (a) one-third (1/3) of the Contingent Cash Consideration and (b) Contingent Shares having a Market Value equal
to one-third (1/3) of the € 6,900,000 (as calculated pursuant to Section 4.2 and adjusted pursuant to Section 4.3) shall be
paid or issued, as applicable, to the Shareholders in accordance with Sections 4.3 and 4.4; provided, however, no Contingent Shares
shall be issued to any Shareholder who is in material violation of, or breach with respect to the Shareholders' Agreement, or to
any Officer or Director who is in material violation of, or breach with respect to any employment, non-compete or other agreement
between such person and the Purchaser or the Company (or any Subsidiary of either), the fact of such material violation or breach
to be determined in the reasonable, good faith, discretion of Purchaser and disputed in accordance with Section 19.

 

4.2         The
Contingent Shares issuable upon the satisfaction of any Target shall be the quotient of the following:

 

Contingent Shares = portion of Euro 6,900,000
payable upon satisfaction of such Target or Targets

Market Value

 

provided that if the Market Value of
such Contingent Shares is less than the Benchmark Value, then: (i) the number of Contingent Shares to be issued shall be equal
to that portion of € 6,900,000 payable upon satisfaction of such Target or Targets divided by the Benchmark Value and
(ii) the difference between the Benchmark Value and Market Value (per Contingent Share) shall be paid in cash (Euros), in accordance
with Section 4.4

 

    	- 13 -

    	 

    

 

The Contingent Cash Consideration and/or the
Contingent Shares may be reduced from time to time by all or a portion of the Indemnification Obligations in accordance with Schedule
6, Section 2.2.

 

4.3        Within
sixty (60) days after the satisfaction of a Target, any Contingent Cash Consideration due the Shareholders shall be paid by wire
transfer of immediately available funds denominated in Euros to the Shareholders in accordance with Schedule 1. Any such payments
of Contingent Cash Consideration shall include interest accruing at two percent (2%) per annum, calculated on the basis of a 365
day year; from the date of Completion to the date such payment is made.

 

4.4         A
certificate evidencing the Contingent Shares due with respect to satisfaction of a Target shall be sent by the Purchaser (or its
transfer agent) to each respective Shareholder in accordance with Schedule 1 within sixty (60) days of satisfaction of such Target.

 

4.5         Prior
to the Sale of the Company, the payment of all unpaid Contingent Cash Consideration and the issuance of any then unissued Contingent
Shares (less any amounts withheld in accordance with the provisions set forth in Schedule 6, Section 2.2) shall automatically be
accelerated such that the Purchaser shall, immediately prior to consummation of such Sale of the Company, pay all unpaid Contingent
Cash Consideration and issue all unissued Contingent Shares as set forth herein.

 

4.6         As
soon as practicable, but no later than the thirtieth (30th) day after the applicable Target is satisfied, the Purchaser (or its
agent) shall prepare in good faith and deliver to the Shareholders a statement setting forth in reasonable detail (a) the Target
achieved and (b) the Contingent Consideration due as a result thereof.

 

4.7         Until
the expiration of the Survival Period, each of the Shareholders hereby covenants and agrees that such Shareholder shall remain
both the record and beneficial holder of all such Contingent Shares in a given year subject to the Indemnification Obligations
held by such Shareholder and shall not sell, transfer, assign, hypothecate, pledge or otherwise encumber such Contingent Shares
except in accordance with the Laws of descent and distribution upon the death of such Shareholder; provided, however that in all
cases such Contingent Shares shall remain subject to this Section 4.7 and provided, further, that upon the expiration of the Survival
Period, such Shareholder shall only effect a sale, transfer, assignment, hypothecation, pledge or other Encumbrance of such Contingent
Shares in accordance with (i) French securities Laws (as evidenced by an opinion of counsel) or an applicable exemption therefrom
and (ii) the Shareholder Agreement.

 

4.8         Unless
and until the Contingent Shares become due pursuant to this Section 4, the Shareholders shall have no rights, title or interest
in any securities or other property received by Shareholders of the Purchaser as a result of any stock split or combination of
the Purchaser, payment of a stock dividend or other stock distribution in

 

    	- 14 -

    	 

    

 

or on Purchaser
Shares, or change of Purchaser Shares into any other securities pursuant to or as a part of a merger, consolidation, acquisition
of property or stock, reorganization or liquidation involving the Purchaser.

 

4.9        No fractional
Contingent Shares shall be issued and no certificates or scrip for any such fractional Contingent Shares shall be issued. Any Shareholder
who would otherwise be entitled to receive a fraction of a Contingent Share shall, in lieu of such fraction, be paid in cash the
amount in Euro (rounded up to the nearest whole Euro cent) determined by multiplying such fraction of a Contingent Share by the
greater of (i) the Market Value or (ii) the Benchmark Price.

 

4.10      The
Purchaser shall use commercially reasonable efforts to extend or renew all corporate approvals and authorizations necessary to
issue the Contingent Shares in accordance with the terms of this Agreement. If (i) the approvals and authorizations to issue the
Contingent Shares have not been renewed or extended by the end of the twenty- sixth (26th) full month following the Completion Date
or (ii) if any extensions to the corporate approvals or authorizations are not subsequently extended prior to the expiration of
the approvals or authorizations then in effect to issue the Contingent Shares, then subject to Section 4.3, the Purchaser agrees
that all Contingent Shares shall immediately be deemed to have been fully earned and shall be issued as soon as practicable (but
in any event prior to the expiration of the approvals and authorizations) to each Shareholder in accordance with Schedule 1. The
Purchaser shall also provide notice to the Shareholders, in a commercially reasonable manner, following any non-renewal of the approvals
and authorizations necessary to issue the Contingent Shares.

 

5. ROYALTY PAYMENTS AND
OBLIGATIONS.

 

5.1         In
further consideration of the transaction contemplated hereby, the Purchaser .hereby agrees to pay to the shareholders a portion
of the annual Net Sales of the Product or any Substitute Product (if Purchaser commercializes such Substitute Product in lieu of
the Product) during the period set forth in Section 5.4 hereof (the "Royalty Payment"). All Royalty Payments shall be
made to the Shareholders in accordance with Schedule 1 within ninety (90) days of such Royalty Payment becoming due and payable.
Royalty Payments being due in one year shall not be indicative of, or infer that, Royalty Payments shall be due in subsequent years.

 

5.2         Provided
the Gross Profit Margin in a given year with respect to the relevant Net Sales is in excess of thirty percent (30%), then Purchaser
shall make Royalty Payments in accordance with the following: (i) with respect to Net Sales from 0 to $50,000,000, the Shareholders
shall be entitled to a Royalty Payment equal to [*] ([*]%) of such Net Sales, (ii)

 

Certain confidential information has been omitted from this
document, as indicated by the notation “[*]”. The omitted information has been filed on a confidential basis with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

 

    	- 15 -

    	 

    

 

with respect to Net Sales from $50,000,000
to $100,000,000, the Shareholders shall be entitled to a Royalty Payment equal to [*] percent ([*]%) of such Net Sales, and (iii)
with respect to Net Sales equal to or in excess of $100,000,000, the Shareholders shall be entitled to a Royalty Payment equal
to [*] percent ([*]%) of such Net Sales. For the avoidance of doubt, in all cases where the Gross Profit Margin is less than thirty
percent (30%) of the Net Sales, no Royalty Payments shall be due from Purchaser to the Shareholders in connection with such Net
Sales. For purposes of this Section 5.2, any sales reflected in Euros shall be converted to US Dollars in accordance with Section
20.

 

5.3         For
the purpose of determining the Royalty Payments with respect to sales of Combination Products, Net Sales will be determined by
multiplying the Net Sales of the Combination Product by a fraction, the numerator of which shall be the per unit retail selling
price of the Product included in the Combination Product sold as a separate stand-alone item, and the denominator of which shall
be the per unit retail selling price of the Combination Product. If there is no established current retail selling price for the
Product or Substitute Product sold separately, but there is an established current retail selling price for the other products
sold in combination with the Product or Substitute Product (the "Other Product"), then the Net Sales price of the Product
or Substitute Product sold in such Combination Product will be (i) the Net Sales of the Combination Product less (ii) the Net Sales
of the Combination Product multiplied by a fraction, the numerator of which shall be the per unit retail selling price of the Other
Product sold separately, and the denominator of which shall be the per unit retail selling price of the Combination Product. If
there is no established per unit retail selling price for the Product or the Other Product, then, the Net Sales price of the Product
or Substitute Product included in such Combination Product will be determined by the Purchaser in good faith using commercially
reasonable methods in accordance with generally accepted cost accounting principles consistently applied.

 

5.4         The
Purchaser's obligation with respect to the Royalty Payments shall commence on the earlier of the date of the First Commercial Sale
of the Product or Substitute Product by the Company, a Subsidiary or any of their Affiliates. Royalty Payments will be paid by
Purchaser hereunder until the earlier of (i) ten (10) years following the First Commercial Sale of the Product or (ii) ten (10)
years following the First Commercial Sale of any Substitute Product. For the purposes of clarity, the Shareholders shall only receive
Royalty Payments with respect to either the Product or the Substitute Product, which shall be determined as the first to consummate
a First Commercial Sale.

 

5.5         Royalty
Payments shall be calculated as of the end of each calendar quarter in Euro, with Net Sales in any foreign currency to be converted
into Euro at the conversion rate set forth in the Financial Times (London Edition) during such quarter. Royalty Payments shall
be paid to the Shareholders in Euro within ninety (90) days following the end of each fiscal

 

Certain confidential information has been omitted from this
document, as indicated by the notation “[*]”. The omitted information has been filed on a confidential basis with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

 

    	- 16 -

    	 

    

 

year. As soon
as practicable, but in no event later than the sixtieth (60th) day following the end of Purchaser's fiscal year during which Royalty
Payments are due, the Purchaser shall deliver to the Shareholders a statement (the "Royalty Statement") setting forth
the Net Sales for the fiscal year pursuant to which the Royalty Payment is being made, and setting forth: (i) the total number
of units of the Product or Substitute Product sold by country, (ii) the gross sales of the Product or Substitute Product in the
local currency and the Euro conversion and (iii) an analysis of the manner in which the Royalty Payment was calculated. Unless
the Majority Shareholders deliver a written objection to the Purchaser within thirty (30) days following its receipt of the Royalty
Statement (the "Royalty Payment Objection Period"), the Royalty Payments set forth on the Royalty Statement shall be
deemed final and binding on the Shareholders. Any notice of objection by the Majority Shareholders must be timely and specify the
items or calculations with which such Majority Shareholders reasonably takes issue. If the Majority Shareholders object in accordance
with the previous sentence, Purchaser and the Majority Shareholders shall settle such dispute in accordance with the provisions
set forth in Section 19 below, with such resolution applying pro rata to all Shareholders.

 

5.6         The
Purchaser shall maintain and shall require its Subsidiaries, licensees, and sublicensees (if applicable) to maintain accurate books
and accounts of record in connection with the sale by or for it of the Product or Substitute Product and any Combination Product
in sufficient detail to permit accurate determination of all figures necessary for verification of the Royalty Payments. Such records
shall be maintained for a period of five (5) years from the end of each year in which sales occurred. To ensure that the proper
Royalty Payment is made, the Majority Shareholders shall have the right, at their own expense, to cause qualified certified public
accountants of its choice to audit the Purchaser's books and records pertaining solely to Net Sales of the Product or any Substitute
Product. Such audits shall take place during Purchaser's normal business hours and not more frequently than once per calendar year.
Prior to conducting an audit, the Majority Shareholders will provide at least ten (10) days written notice to Purchaser. If any
such audit reveals that a shortfall in Royalty Payments has occurred, then Purchaser shall promptly following (i) the receipt of
notice of a shortfall by the Majority Shareholders in the event that Purchaser does not dispute the audit results or (ii) the resolution
of any such dispute, pay to the Shareholders the amount of such shortfall plus interest accrued thereon at the average prime rate
announced by Citibank, N .A. during the period from the date the Royalty Payment was originally due and ending on the date that
the shortfall and interest is paid. If the parties have a good faith dispute regarding the results of the audit, they shall first
seek to amicably resolve the dispute through discussion. If the parties are unable to resolve the dispute, they shall jointly appoint
an independent certified public accountant to resolve the dispute and will abide by the decision reached by such independent certified
public accountant. If the parties are unable to agree on the selection of an independent certified public accountant, they shall
each appoint one such firm, and the two so selected shall chose a third independent certified public accountant who shall resolve
the dispute and whose decision shall be binding on the parties. The parties will share equally the fees and expenses of any independent
certified public accountant engaged to resolve any dispute pursuant to this Section 5.6; provided, however, that if (a)
the

 

    	- 17 -

    	 

    

 

independent certified public accountant
selected in accordance with the immediately preceding sentence determines the existence of a Net Sales deficiency that is greater
than or equal to five percent (5%) of the Net Sales originally reported by the Purchaser, the Purchaser shall pay all fees and
expenses of the independent certified public accountant engaged to resolve such dispute or (b) that the independent certified public
accountant confirms the Net Sales originally reported by the Purchaser or determines the existence of a Net Sales surplus of the
Net Sales originally reported by the Purchaser, the Majority Shareholders shall pay all fees and expenses of the independent certified
public accountant engaged to resolve such dispute.

 

5.7       Any Tax that Purchaser is
required to withhold under applicable Law and pay on behalf of the Shareholders hereunder with respect to any Royalty Payment shall
be deducted from and offset against said Royalty Payment prior to remittance; provided, however, that in regard to any Tax
so deducted, Purchaser shall give or cause to be given to the Shareholders such assistance as may reasonably be necessary to enable
the Shareholders to claim exemption therefrom or credit therefor, and in each case shall furnish the Shareholders of proper evidence
of Taxes paid on behalf of the Shareholders. If a Tax treaty is applicable or in effect and the Majority Shareholders request Purchaser
utilize such treaty, the Purchaser shall use reasonable efforts in complying with the treaty and each Shareholder shall give or
cause to be given to Purchaser such assistance as may be reasonably necessary to enable Purchaser to utilize such treaty.

 

5.8         From the
Completion Date through the entirety of the period when any Royalty Payments and/or Contingent Consideration (collectively, the
"Earn Out") may be or become payable by the Purchaser to the Shareholders in accordance with this Agreement, the Purchaser
shall: (i) for the purpose of protecting the rights of the Shareholders to receive the Earn Out under the terms of this Agreement,
use commercially reasonable efforts to avoid taking any action or permitting any omission which is intended to deter the Shareholders'
ability to earn the Earn Out; and (ii) use commercially reasonable efforts to collect all Net Sales in a timely manner.

 

6. CONDITIONS

 

6.1        The
sale and purchase of the Company Shares and the completion of the other transactions contemplated by this Agreement and the Transaction
Documents are in all respects conditional upon those matters listed in Schedule 2, provided that: (i) the Purchaser may, in its
sole and absolute discretion, waive any of the conditions precedent which must be satisfied by the Shareholders and Company set
forth on Schedule 2A by written notice to the Shareholders, (ii) the Shareholders may, in their sole and absolute discretion, waive
any of the conditions precedent which must be satisfied by the Purchaser set forth on Schedule 2B by written notice to the Purchaser,
and (iii) in no instance may any party hereto waive the conditions set forth on Schedule 2C.

 

6.2         The Company and
the Shareholders covenant and agree to use commercially reasonable efforts to cause the conditions set forth in Schedule 2 (and
applicable to such party) to be fulfilled as soon as possible after the date of this Agreement (to the reasonable

 

    	- 18 -

    	 

    

 

satisfaction of the Purchaser); and the Purchaser
covenants and agrees to use commercially reasonable efforts to cause the conditions set out in Schedule 2 (and applicable to such
party) to be fulfilled as soon as possible after the date of this Agreement.

 

6.3         None of Purchaser,
the Company or the Shareholders may rely on the failure of any condition set forth in Schedule 2 to be satisfied if such failure
was caused by such party's failure to comply with or perform any of its covenants or obligations set forth in this Agreement.

 

7. CONDUCT OF BUSINESS
BEFORE COMPLETION

 

7.1        The
Shareholders shall take all reasonable actions within their power to procure, and the Company shall procure, that the Business
is conducted in the ordinary course during the period from the date of this Agreement to Completion. Without limitation to the
generality of the foregoing, the Shareholders shall take all commercially reasonable actions within their power to procure, and
the Company shall use its best efforts to procure, that between the date of this Agreement and Completion neither the Company nor
any Company Subsidiary will undertake any of the Restricted Actions without the prior written consent of the Purchaser.

 

7.2         Sub-Section 7.1 shall not
operate so as to restrict or prevent:

  

(i)         any
matter reasonably undertaken by the Company or Company Subsidiary in an emergency or disaster situation with the intention of minimizing
any material adverse effect thereof (and of which the Purchaser will be notified in advance, where such advance notice is commercially
practicable, failing which the Purchaser shall be notified promptly thereafter) only for so long as such emergency or disaster
situation continues and/or solely to the extent the Company reasonably considers necessary to mitigate the effects of such emergency
or disaster situation; or

 

(ii)       the
completion or performance of any obligations undertaken in the ordinary course of business pursuant to or matters contemplated
by any agreement or arrangement entered into by the Company or Company Subsidiary prior to the date of this Agreement which does
not in the aggregate exceed $10,000; or

 

(iii)       any matter contemplated
in this Agreement; or

 

(iv)       any matter undertaken
with the prior written approval of the Purchaser.

 

7.3         From
the date of this Agreement until Completion, the Shareholders shall use commercially reasonable efforts to procure and the Company
shall use its best efforts to procure that each of the Company and Company Subsidiaries shall give the Purchaser and its authorized
representatives reasonable access to books, records, accounts, documents, personnel and offices of the Company and Company Subsidiaries.

 

    	- 19 -

    	 

    

 

7.4         Neither
the Shareholders nor the Company shall be obliged to grant access pursuant to Section 7.3 to the extent that such access materially
interferes with the ability of the Company or Company Subsidiaries to conduct the Business.

 

7.5         From
the date of this Agreement until Completion, the Company shall use its best efforts to provide the Purchaser and its authorized
representatives with notice of any enquiry or investigation of, or any material communication, material correspondenceor material
request received from, a Governmental Entity in relation to the Business, the Company or any Company Subsidiary within twenty-four
(24) hours of becoming aware, or at such time it should reasonably be aware thereof.

 

8. COMPLETION

 

8.1         Completion
shall take place on the Completion Date at the offices of Ellenoff Grossman & Schole LLP, 150 East 42nd Street, New York, NY
10017, or at such other venue as may be agreed in writing between the Majority Shareholders and the Purchaser.

 

8.2         Except
with respect to any condition on Schedule 2C which shall not be waived, each of the conditions to Completion set forth on Schedule
2A and 2B shall have been satisfied or waived by the party benefiting from such condition.

 

8.3         If the
respective obligations of the Company, Shareholders and/or the Purchaser pursuant to Schedule 2 have not been satisfied or waived
by the Completion Date the Purchaser or the Company, as the case may be, shall have the following options: (i) defer Completion,
(ii) proceed to Completion as far as practicable (without limiting the parties' respective rights under this Agreement), or (iii)
in the event that Completion has not occurred by the End Date, terminate this Agreement by notice in writing to the other parties
hereto, provided that the reason Completion has not occurred by the End Date is not attributable to any act or omission
by the party giving such notice.

 

9.
Representations And Warranties; Limitations; Cure Period

 

9.1        Unless
such representation or warranty is limited therein, each of the representations and warranties set forth on Schedule 3 shall survive
until the expiration of the Survival Period.

 

9.2       The
representations and warranties set out in separate paragraphs of Schedule 3 shall be separate and independent and (except as expressly
provided otherwise in this Agreement) no representation or warranty shall be limited by reference to any other representation or
warranty.

 

9.3        The
representations and warranties are qualified by and are subject to any facts and circumstances fairly disclosed in this Agreement
or the Disclosure Letter with sufficient detail to allow a reasonably sophisticated person to evaluate such matter.

 

    	- 20 -

    	 

    

 

9.4         If
there has been a breach by any Shareholder of the representations and warranties set forth in Section 17.2 of Schedule 3, then,
and only if such breach is curable, such Shareholder shall have twenty (20) calendar days to cure such breach, provided such Shareholder
exercises commercially reasonable best efforts to cure such breach. Notwithstanding any cure by the Shareholder or the effectuation
of a cure by the Shareholder, the Purchaser may seek indemnification pursuant to the Indemnification Obligations for any Damages
incurred by Purchaser as a result of such breach during the cure period.

 

    	- 21 -

    	 

    

 

10. SURVIVAL FOLLOWING COMPLETION

 

10.1      Any
provision of this Agreement which is capable of being performed in accordance with the terms of this Agreement after Completion,
but which has not been performed at or before Completion, the representations and warranties and all covenants and other undertakings
contained in or entered into pursuant to this Agreement that are intended to be performed after Completion shall remain in full
force and effect notwithstanding Completion, subject to the provisions contained in Schedule 6.

 

11.
REMEDIES AND WAIVERS

 

11.1
     Except as otherwise expressly provided in this Agreement, no delay or omission by any party to this Agreement in exercising
any right, power or remedy provided by Law or under this Agreement or any other documents referred to in it shall affect that right,
power or remedy or operate as a waiver thereof.

 

11.2       Except
as otherwise expressly provided in this Agreement, the single or partial exercise of any right, power or remedy provided by Law
or under this Agreement shall not preclude any other or further exercise of it or the exercise of any other right, power or remedy.

 

11.3       Except
as otherwise expressly provided in this Agreement, the rights, powers and remedies provided in this Agreement are cumulative and
not exclusive of any rights, powers and remedies provided by Law.

 

11.4       The
Purchaser shall be entitled, in addition to any other remedy to which it may be entitled at Law or in equity, to seek injunctive
relief and/or to compel specific performance to prevent breaches by any Shareholder and/or Company of any covenant or agreement
contained in this Agreement. Accordingly, the Shareholders and the Company hereby agree the Purchaser is entitled to an injunction
prohibiting any conduct by the Shareholders and/or the Company in violation of this Agreement and the Shareholders or the Company,
as the case may be, shall not seek the posting of any bond in connection with such request for an injunction. All costs and expenses,
including reasonable attorneys' and experts' fees incurred by the parties in connection with any action for enforcement pursuant
to this Section 11.4 shall be borne by the non-prevailing party or parties.

 

11.5       The
Shareholders shall be entitled, in addition to any other remedy to which they may be entitled at Law or in equity, to seek injunctive
relief and/or to compel specific performance to prevent breaches by the Purchaser of any covenant or agreement contained in this
Agreement. Accordingly, the Purchaser hereby agrees the Shareholders are entitled to an injunction prohibiting any conduct by the
Purchaser in violation of this Agreement 'and Purchaser shall not seek the posting of any bond in connection with such request
for an injunction. All costs and expenses, including reasonable attorneys' and

 

    	- 22 -

    	 

    

 

experts'
fees incurred by the parties in connection with any action for enforcement pursuant to this Section 11.5 shall be borne by the
non-prevailing party or parties.

 

12. ASSIGNMENT

 

12.1       Neither
the Company nor the Shareholders shall assign, or purport to assign, all or any part of the benefit of, or its rights or benefits
under, this Agreement or any causes of action arising hereunder without the prior written consent of the Purchaser, other than
an assignment or transfer by operation of descent and distribution. The Purchaser may assign the benefit of all or any of the Company
or Shareholder obligations under this Agreement and/or any other benefit to the Purchaser arising under or out of this Agreement,
subject to the provisions contained in Section 4.5 above.

 

12.2      This
Agreement shall be binding upon, inure to the benefit of and be enforceable by the parties and their respective successors in title
and permitted assigns.

 

13. ENTIRE AGREEMENT; AMENDMENT

 

13.1      This
Agreement and the documents or instruments referred to herein, including any exhibits attached hereto and the Schedules referred
to herein, which exhibits and Schedules are incorporated herein by reference, the Disclosure Letter, the Shareholder Agreement,
the Side Letter and the Deed of Adherence (collectively, the "Transaction Documents"), constitute the whole and only
agreement among the parties relating to subject matter provided for herein and supersede all prior agreements and the understandings
among the parties with respect to such subject matter. The parties acknowledge and agree they have not entered into this Agreement
or any of the other documents or agreements referred to herein in reliance or any representation or warranty except for those set
forth in the Transaction Documents.

 

13.2      Prior
to Completion, this Agreement may only be amended in writing signed by or on behalf of the Purchaser and the Company. Beginning
at Completion, this Agreement may only be amended in writing signed by or on behalf of the Purchaser and the Majority Shareholders.

 

14. NOTICES

 

14.1       All
notices, statements or other documents which are required or contemplated by this Agreement shall be: (i) in writing and delivered
personally or sent by first class registered or certified mail, overnight courier service or facsimile transmission to the address
designated in writing, (ii) by facsimile to the number most recently provided to such party or such other address or fax number
as may be designated in writing by such party and (iii) by electronic mail, to the electronic mail address most recently provided
to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication
so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following
receipt of written confirmation, if sent by facsimile transmission

 

    	- 23 -

    	 

    

 

or email, one (1) business day after
delivery to an overnight courier service or five (5) days after mailing if sent by mail.

 

 

14.2     
Notices under this Agreement shall be sent to:

 

(a)      if
to a Shareholder, at the address and/or facsimile number set forth on such Shareholder's signature page

 

(b)        if to the Company:

 

BioSynthema, Inc.

4041 Forest Park Avenue

S1.Louis, MO 63108

Attn: General Counsel

Fax: (314) 615-6901

 

with a copy to (which shall
not constitute notice):

 

Palank
& Associates

1034 S. Brentwood Blvd., Suite
1630

S1.Louis, MO 63117

Attn: Mary A. Palank, Esq.

Fax:
(314) 863-3301

 

(c)       if to the Purchaser:

 

Advanced Accelerator Applications,
S.A.

20, rue Diesel

01630 Saint Genis Pouilly, France

Fax: (33)-4-50-99-3070

 

with a copy to (which shall
not constitute notice):

 

Ellenoff Grossman & Schole LLP

150 East 42nd Street, 11th
Floor

New York, NY 10017

Attn: Douglas S. Ellenoff,
Esq.

Fax: (212) 370-7889

 

15. CONFIDENTIALITY

 

15.1       Each
party to this Agreement shall (and shall procure that each of its Representatives shall) treat as confidential all information
(whether written or transferred or obtained orally, visually, electronically or by any other means) obtained in connection with
the preparation for and negotiation of the sale and purchase of the Company Shares or as a result of entering into or performing
this Agreement (or, with respect to

 

    	- 24 -

    	 

    

 

confidential information relating
to the Business, the Company and Company Subsidiaries known by any Shareholder, obtained in connection with the Business, the Company
and Company Subsidiaries prior to Completion) which relates to:

 

(a)       (in relation to the obligations
of the Purchaser under this Section 15) any confidential information received or held by the Purchaser (or any of its Representatives)
where such information relates to the Shareholders or any of them or, prior to (but not after) Completion, the Company or any Company
Subsidiary;

 

(b)       the provisions of
this Agreement;

 

(c)       the negotiations relating
to this Agreement;

 

(d)       the subject matter
of this Agreement; or

 

(e)      (in
relation to the obligations of each of the Shareholders, this Section 15) any confidential information received or held by such
Shareholder (or any of their Representatives) where such confidential information relates to the Purchaser or, following Completion,
the Company, any Company Subsidiary or the Business including any confidential Intellectual Property owned by the Purchaser, the
Company or any Company Subsidiary or any Licensed Intellectual Property (as defined in Schedule 3)

 

(the abovementioned items of information
shall, for the purposes of this Section 15, be referred to herein as "Confidential Material"). Notwithstanding the foregoing,
Confidential Material shall not include any information of the disclosing party or its Affiliates (the "Disclosing Party")
that (i) is already known to the receiving party or its Affiliates (the "Receiving Party") at the time of its disclosure;
(ii) is or becomes publicly known through no wrongful act of the Receiving Party; (iii) is independently developed by the Receiving
Party without use or access to the Disclosing Party's Confidential Material; (iv) is communicated to a third party with the express
written consent of the Disclosing Party unless such third party is bound by a confidentiality agreement among the parties hereto;
or (v) is communicated to the Receiving Party by a third party who is not under an obligation not to disclose the information.

 

15.2      Notwithstanding
the other provisions of this Section 15, any party to this Agreement and any of such party's Representatives may disclose Confidential
Material:

 

(a)        if
and to the extent that such party or such Representative, as the case may be, can demonstrate that disclosure is required by Law
in any applicable jurisdiction;

 

    	- 25 -

    	 

    

 

(b)       if
and to the extent that such party or such Representative, as the case may be, can demonstrate that disclosure is required by any
securities exchange or Governmental Entity to which that party is subject wherever situated;

 

(c)        for the purpose of
any Proceedings;

 

(d)       to
its Representatives on a need to know basis provided that each person to whom disclosure is made is advised of the confidentiality
obligations under this Agreement and agrees to be bound thereby;

 

(e)        if and
to the extent that the Shareholders (in respect of disclosure by the Purchaser or its Representatives, including the Company, following
Completion) or the Purchaser (in respect of disclosure by any Shareholder or their respective Representatives and the Company prior
to Completion) has given prior written consent to the disclosure; or

 

(f)        to
an insurer under an insurance policy taken out or intended to be taken out to benefit the Company or any Company Subsidiary, to
the extent that such disclosure is required to determine the terms of that insurance policy.

 

Any information
to be disclosed pursuant to paragraphs (a) or (b) of this Section 15.2 shall be disclosed only after consultation with the other
parties to this Agreement to whom such information is relevant and the party intending to disclose the Confidential Material shall
take into account the reasonable comments or requests of such other party.

 

15.4       The
restrictions contained in this Section 15 shall continue to apply after Completion or termination of this Agreement for a period
of five (5) years.

 

15.5      Each
party to this Agreement shall use commercially reasonable efforts to procure that its respective Representatives also comply with
the provisions of Sections 15.1 and 15.2, mutatis mutandis. Each party to this Agreement shall be responsible for breach of the
above confidentiality undertaking by it or its Representatives.

 

15.6       Each
party to this Agreement shall only use (or permit the use by its Representatives of) the Confidential Material received or held
by it or its Representatives for the purposes of performing the obligations under this Agreement or for the purposes of establishing
a defense in the course of any Proceedings.

 

16. COSTS AND EXPENSES

 

16.1       All
expenses incurred in connection with the preparation, negotiation and execution of this Agreement and the transactions contemplated
hereby shall be paid by the party incurring such expenses, whether or not the sale and purchase of the Company Shares or any other
related transaction is completed

 

    	- 26 -

    	 

    

 

17. COUNTERPARTS

 

17.1     This
Agreement may be executed in any number of counterparts, and by the parties to it on separate counterparts, but shall not be effective
until each party has executed at least one counterpart.

 

17.2      Each
counterpart shall constitute an original of this Agreement, but all the counterparts shall together constitute but one and the
same instrument.

 

18. TERMINATION

 

18.1       This
Agreement may be terminated at any time prior to Completion as follows:

 

(a)       by mutual written consent
of the parties as duly authorized by the Purchaser's board of directors, the holders of at least 2/3 of the outstanding Company
Shares as of the date hereof (the "Majority Shareholders") and the Company's board of directors;

 

(b)       by either
the Purchaser or the Company if Completion has not occurred by the End Date (and all conditions set forth on Schedule 2 have been
satisfied);

 

(c)       by written
notice of the Purchaser, if there has been a breach by the Company or any Shareholder of any of their respective representations,
warranties, covenants or agreements contained in this Agreement, or if any representation or warranty of the Company or any Shareholder
shall have become untrue or inaccurate; provided, however, the Company, or the Shareholder, as the case may be, shall
have thirty (30) calendar days to cure such breach from their receipt of notice by the Purchaser;

 

(d)       by
written notice by the Majority Shareholders, if there has been a breach by the Purchaser of any of its respective representations,
warranties, covenants or agreements contained in this Agreement, or if any representation or warranty of the Purchaser shall have
become untrue or inaccurate; provided, however, the Purchaser shall have thirty (30) calendar days to cure such breach from
their receipt of notice by the Majority Shareholders; and

 

(e)        in accordance with Section
8.3.

 

18.2      In
the event of the termination of this Agreement in accordance with Section 18.1(a) or 18.1(b), this Agreement shall forthwith become
void, and there shall he no liability on the part of any party hereto or any of their respective Affiliates or the directors, officers,
partners, members, managers, employees, agents or any other person related to each of them, and all rights and obligations of each
party hereto shall cease, except for the Surviving Provisions.

 

    	- 27 -

    	 

    

 

19. DISPUTE RESOLUTION

 

19.1       The
Parties shall attempt to resolve any dispute arising out of or relating to this Agreement, promptly by good faith negotiation among
representatives who have authority to resolve the controversy. If such dispute is not resolved, any Party may give the other applicable
Parties written notice of such dispute and within twenty (20) calendar days after delivery of such notice, each receiving Party
shall submit to the other applicable Parties a written response. The notice and the response shall include (i) a statement of the
applicable Party's concerns and perspectives on the dispute, (ii) a summary of supporting facts and circumstances and (iii) the
identity of the representative who will represent such Party. Within forty-five (45) calendar days after delivery of the original
notice, the representatives of the applicable Parties shall confer, either in person, telephonically, by videoconference or otherwise,
at a mutually acceptable time and place, and thereafter as often as they reasonably deem necessary, for the purposes of resolving
such dispute. If such dispute remains unresolved following thirty (30) calendar days, then each party shall have the option of
appointing an independent advisor reasonably considered an expert in the area of the dispute. Such independent advisors shall meet
with the Parties at a mutually agreed upon time and place for the purpose of resolving the dispute (within thirty (30) calendar
days of the period described above). All negotiations pursuant to this subsection are confidential and shall be treated as compromise
and settlement negotiations for purposes of applicable rules of evidence.

 

20. CURRENCY CONVERSIONS

 

20.1       Notwithstanding
anything to the contrary contained in this Agreement, all conversions between currencies shall be in accordance with the standard
currency conversion policies and procedures of the Purchaser, as recommended by Purchaser's auditors.

 

21. SEVERABILITY

 

21.1       If
any provision of this Agreement is held to be invalid or unenforceable, then such provision shall (so far as it is invalid or unenforceable)
be given no effect and shall be deemed not to be included in this Agreement but without invalidating any of the remaining provisions
of this Agreement.

 

22. CHOICE OF GOVERNING LAW; VENUE; SERVICE
OF PROCESS AND JUDGMENTS

 

22.1      The terms of this
Agreement and the relations between the parties hereto shall be governed by and are subject to the laws of France, without regard
to conflicts of law principles. Each of the Parties hereby irrevocably submits to the jurisdiction of the courts located in France
or first in the United States District Court for the Eastern District of Missouri and thereafter (and only if dismissed or transferred
by the United States Court for the Eastern District of Missouri for lack of jurisdiction) in any court of competent jurisdiction
in St. Louis, Missouri, in any action, suit or proceeding brought against any party hereto under

 

    	- 28 -

    	 

    

 

or in connection with this
Agreement, and hereby irrevocably waives; to the fullest extent each of them may effectively do so, any defense based on improper
jurisdiction or venue including, without limitation, defenses based on forum non-conveniens. The Parties further agree that a judgment
against such party in France, the United States District Court for the Eastern District of Missouri or, as applicable, any court
of competent jurisdiction located in St. Louis, Missouri, shall be conclusive and binding upon it and may be enforced in any other
jurisdiction to the fullest extent applicable.

 

23. PRESS ANNOUNCEMENTS

 

24.1       Purchaser,
the Company and the Shareholders agree that no Press Announcement shall be issued by any party or any of their Affiliates without
the prior written consent of the other of them (which consent shall not be unreasonably withheld, conditioned or delayed); provided,
that the consent of the Majority Shareholders shall constitute the consent of the Shareholders, except as such release or announcement
may be required by applicable Law, in which case the applicable party shall use reasonable efforts to allow the other of them reasonable
time to comment on such release or announcement in advance of such issuance; provided, however, that either Purchaser or the Company
may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences
or financial analyst conference calls, so long as any such statements are not inconsistent with previous Press Announcements.

 

24. FURTHER ASSURANCES; MUTUAL
DRAFTING

 

25.1       Each
party agrees to cooperate fully with the other parties and to execute such further instruments, documents and agreements and to
give such further written assurances as may be reasonably requested by any other party to evidence and reflect the transactions
described herein and contemplated hereby and to carry into effect the intents and purposes of this Agreement.

 

25.2        This Agreement is the joint
product of the Company, the Shareholders and the Purchaser and each provision hereof has been subject to the mutual consultation,
negotiation and agreement of such parties and shall not be construed for or against any party hereto

 

[Signature Page Follows]

 

    	- 29 -

    	 

    

 

In witness
whereof, the parties hereto have caused this Agreement to be executed and delivered as of the date first set forth above.

 

	ADVANCED ACCELERATOR APPLICATIONS, S. A.
	 	 
	By: /s/ Stefano Buono	
	Name: Stefano  Buono
	Title: Chairman and Chief Executive Officer

	BIOSYNTHEMA INC.
	 
	By: /s/ Jack L. Erion
	Name: Jack L. Erion
	Title: Chief Executive Officer and President

 

Company and Purchaser Signature Page to Stock Purchase
        Agreement 

 

    	- 30 -

    	 

    

  

 

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: W. Bakker	 
	 	 
	 	/s/ W.H. Bakker	W.H. Bakker
	Name:	Signature	Print name
	 	 	 
	Title:	Director	 
	 	 	 
	Date:	May 27, 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

    	31

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: Boesen B.V	 	 	 
	 	 	 	 
	 	/s/ J.G.R Boesen	/s/ J.J.B. Boesen	J.G.R Boesen	J.J.B. Boesen
	Name:	Signature	 	Print name	 
	 	 	 	 	 
	Title:	Director	Managing Director	 	 
	 	 	 	 	 
	Date:	28 May 2010	May 28, 2010	 	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

    	32

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: W. Breeman	 
	 	 
	 	/s/ W. Breeman	W. Breeman
	Name:	Signature	Print name
	 	 	 
	Title:	PhD	 
	 	 	 
	Date:	May 28, 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	33

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: B. D. Burleigh	 
	 	 
	 	/s/ Bruce D. Burleigh	Bruce D. Burleigh
	Name:	Signature	Print name
	 	 	 
	Title:	 	 
	 	 	 
	Date:	25 May 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	34

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: Center for Emerging Technologies	 
	 	 
	 	/s/ William B. Simon	William B. Simon
	Name:	Signature	Print name
	 	 	 
	Title:	VP/COO for Center for Emerging Technologies	 
	 	 	 
	Date:	5/25/2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	35

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: M. de Jong	 
	 	 
	 	/s/ M. de Jong	M. de Jong
	Name:	Signature	Print name
	 	 	 
	Title:	Professor	 
	 	 	 
	Date:	May 30, 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	36

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: J. Erion	 
	 	 
	 	/s/ Jack L. Erion	Jack L. Erion
	Name:	Signature	Print name
	 	 	 
	Title:	President & CEO	 
	 	 	 
	Date:	5/24/2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	37

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: Four Marks Development B.V.	 
	 	 
	 	/s/ H. van Rossem	H. van Rossem
	Name:	Signature	Print name
	 	 	 
	Title:	Principal	 
	 	 	 
	Date:	May 26, 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	38

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: B. Gallagher	 
	 	 
	 	/s/ Brendan Gallagher	Brendan Gallagher
	Name:	Signature	Print name
	 	 	 
	Title:	 	 
	 	 	 
	Date:	5/29/2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	39

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: A. G. Harris	 
	 	 
	 	/s/ Alan Harris	Alan Harris
	Name:	Signature	Print name
	 	 	 
	Title:	 	 
	 	 	 
	Date:	28 May 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	40

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: E. Krenning	 
	 	 
	 	/s/ EP Krenning	Prof. Dr. EP Krenning
	Name:	Signature	Print name
	 	 	 
	Title:	MD, PhD, FRCP	 
	 	 	 
	Date:	29 May 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	41

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: L. Kvols	 
	 	 
	 	/s/ Larry Kvols	Larry Kvols
	Name:	Signature	Print name
	 	 	 
	Title:	 	 
	 	 	 
	Date:	6-1-2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	42

    	 

     

 

 

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: D. Kwekkeboom	 
	 	 
	 	/s/ D. J. Kwekkeboom	D. J. Kwekkeboom
	Name:	Signature	Print name
	 	 	 
	Title:	Dr	 
	 	 	 
	Date:	29./5/2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	43

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: S. Pauwels	 
	 	 
	 	/s/ S. Pauwels	S. Pauwels
	Name:	Signature	Print name
	 	 	 
	Title:	MD, PhD	 
	 	 	 
	Date:	28 May 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	44

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: J. Reubi	 
	 	 
		/s/ J. C. Reubi	J. C. Reubi
	Name:	Signature	Print name
	 	 	 
	Title:	Professor and Head of Division	 
	 	 	 
	Date:	June 3rd 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	45

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: F. Sorenson	 
	 	 
	 	/s/ Ferril M. Sorenson	Ferril M. Sorenson
	Name:	Signature	Print name
	 	 	 
	Title:	 	 
	 	 	 
	Date:	May 31, 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	46

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: J. Spronk	 
	 	 
	 	/s/ Jacob Spronk	Jacob Spronk
	Name:	Signature	Print name
	 	 	 
	Title:	Prof. Dr.	 
	 	 	 
	Date:	29 May 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	47

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: A. van Dulmen	 
	 	 
	 	/s/ Aad van Dulmen	Aad van Dulmen
	Name:	Signature	Print name
	 	 	 
	Title:	Shareholder	 
	 	 	 
	Date:	May 27, 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	48

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: H. van Rooij	 
	 	 
	 	/s/ Hans H. van Rooij	Hans H. van Rooij
	Name:	Signature	Print name
	 	 	 
	Title:	PhD	 
	 	 	 
	Date:	2010/05/27	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	49

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: T. Visser	 
	 	 
	 	/s/ Theo J. Visser	Theo J. Visser
	Name:	Signature	Print name
	 	 	 
	Title:	Professor	 
	 	 	 
	Date:	May 30, 2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	50

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: R. Wolfangel	 
	 	 
	 	/s/ Robert G. Wolfangel	Robert G. Wolfangel
	Name:	Signature	Print name
	 	 	 
	Title:	Regulatory Consultant	 
	 	 	 
	Date:	5-29-2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	51

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: H. Maecke	 
	 	 
	 	/s/ Helmut Maecke	Helmut Maecke
	Name:	Signature	Print name
	 	 	 
	Title:	Professor	 
	 	 	 
	Date:	31-05-2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	52

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

Shareholder: Mallinckrodt
Inc.

 

	By:	/s/ Joe Wuestner	 

 

 

	 	Name:	Joe Wuestner
	 	Title:	VP and Assistant Secretary

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

    	53

    	 

     

In witness whereof, the parties hereto have caused
this Agreement to be executed and delivered as of the date first set forth above.

 

	Shareholder: RRL76, LLC	 
	 	 
	 	/s/ Mary A. Palank	Mary A. Palank
	Name:	Signature	Print name
	 	 	 
	Title:	 	 
	 	 	 
	Date:	5/26/2010	 

 

 

BiosSynthema Inc. Shareholder Signature Page
to Stock Purchase Agreement

 

 

    	54

    	 

     

 

Schedule 1

 

The Shareholders

 

Part I, Shareholder Name and Address;

 

	Name	 	Address
	Willem H. Bakker	 	De Gaarde 17, 3161 CK Rhoon

The Netherlands
	 	 	 
	Wout Breeman	 	Rietgors 6, 3271 XD Mijnsheerenland, The Netherlands
	 	 	 
	B. Daniel Burleigh	 	608 Imperial Drive, O’Fallon, MO 63366 USA
	 	 	 
	Center for Emerging	 	Marcia Mellitz, President, 4041 Forest Park Avenue, St. Louis, MO 63108 USA
	Technology	 	
	 	 	 
	Jeanine Boesen-de-Cock	 	Faunalaan 79-A, 3972 PP Driebergen-Rijsenburg, The Netherlands

	 	 	 
	Marion de Jong	 	Johanna Naberkade 44, 3137 TN, Vlaardingen, The Netherlands
	 	 	 
	Jack L. Erion	 	379 Woodmere Nook Court, St. Charles, MO 63303 USA
	 	 	 
	Dik Kwekkeboom	 	Erasmus Medical Center, Dept of Nuclear Medicine’s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
	 	 	 
	Alan G. Harris	 	190 East 72nd Street, Apt. 32C, New York, NY 10021 USA
	 	 	 
	Brendan Gallagher	 	4131 Laclede Avenue, St. Louis, MO 63108 USA
	 	 	 
	Dr. Eric Krenning	 	Hoflann 71, 3062 JC, Rotterdam – Kralinger, The
    Netherlands
	 	 	 
	Prof. Jean-Claude Reubi	 	Austrasse 4, CH – 3084 Wabern, Switzerland
	 	 	 
	Helmut Maecke	 	Bergfriedwag 7, D-79541 Lorrach, Germany (H) +49-
	7621-10320	 	 
	RRL76, LLC	 	76 Rolling Rock Lane, St. Louis, MO 63124 USA
	 	 	 
	Larry Kvols	 	
        10404 Brigantine Boulevard, Tampa, FL 33615 USA

        

 

    	Schedule 1 to Stock Purchase Agreement
Page 1 of 3

    	 

    

  

	Mallinckrodt Inc.	 	
        c/o Chief Corporate Counsel

        675 McDonnell Boulevard, Hazelwood, MO 63042 USA

	 	 	 
	Dr. Stan Pauwels	 	
        Cliniques Universitaires Saint-Luc

        Avenue Hippocrate 10, B-1200 Brussels, Belgium

	 	 	 
	Ferril Sorenson II	 	302 Chestnut Forest Cove, Fort Wayne, IN. 46814
	 	 	 
	Jaap Spronk 

Netherlands	 	Avenue Concordia 108, 3062LN Rotterdam, the
	 	 	 
	Aad van Dulmen	 	Schoutsakker 4, 1871 CZ Schoorl, The Netherlands
	 	 	 
	Henk van Rossem	 	Wihelminaplantsoen 13, 1601 LS Enkhuizen

The Netherlands
	 	 	 
	Dr. Hans van Rooij	 	OZ Voorburgwal, 109 N. 1012 EM, Amsterdam, The Netherlands
	 	 	 
	Dr. T. J. Visser	 	Linnacusstraat 27, 3172 VW, Poortugaal, the Netherlands
	 	 	 
	Robert Wolfangel, Ph.D.	 	1104 Grenadier Lane, Manchester, MO 63021 USA

 

 

  

    	Schedule 1 to Stock Purchase Agreement
Page 2 of 3

    	 

    

  

Part 2, Shareholder Number of Shares Held;

 

	Name	 	Total 
Shares	 	 	% of

 Total	 	 	Receiving Bank of Shareholder
	H. Rossem	 	 	814196	 	 	 	15.11	%	 	
	RRL76, LLC	 	 	525499	 	 	 	9.75	%	 	 
	J. Erion	 	 	1280639	 	 	 	23.76	%	 	 
	A. Dulmen	 	 	144401	 	 	 	2.68	%	 	 
	F. Sorenson	 	 	29550	 	 	 	0.55	%	 	 
	B. Wolfangel	 	 	197400	 	 	 	3.66	%	 	 
	Jeanine Boesen	 	 	428675	 	 	 	7.95	%	 	 
	Dik Kwekkeboom	 	 	44650	 	 	 	0.83	%	 	 
	Hans van Rooij	 	 	36600	 	 	 	0.68	%	 	 
	E. Krenning	 	 	1260699	 	 	 	23.39	%	 	 
	J. Reubi	 	 	29550	 	 	 	0.55	%	 	 
	H. Maecke	 	 	29550	 	 	 	0.55	%	 	 
	S. Pauwels	 	 	29550	 	 	 	0.55	%	 	 
	M. de Jong	 	 	65010	 	 	 	1.21	%	 	 
	W. Breeman	 	 	26595	 	 	 	0.49	%	 	 
	W. Bakker	 	 	8865	 	 	 	0.16	%	 	 
	T. Visser	 	 	11820	 	 	 	0.22	%	 	 
	L. Kvols	 	 	115010	 	 	 	2.13	%	 	 
	CET	 	 	24000	 	 	 	0.45	%	 	 
	Mallinckrodt	 	 	6000	 	 	 	0.11	%	 	 
	J. Spronk	 	 	217625	 	 	 	4.04	%	 	 
	Alan G. Harris	 	 	62150	 	 	 	1.15	%	 	 
	B.D. Burliegh	 	 	1000	 	 	 	0.02	%	 	 
	B. Gallagher	 	 	1000	 	 	 	0.02	%	 	 
	TOTAL ISSUED SHARES	 	 	5390034	 	 	 	100.00	%	 	 

  

    	Schedule 1 to Stock Purchase Agreement
Page 3 of 3

    	 

    

  

Schedule 2A

(Conditions to Completion)

 

Schedule 2A: Conditions to Completion
by the Purchaser

 

1.           Representations
and Warranties.   The representations and warranties of the Company, the Officers, Directors and Shareholders, as
applicable, shall be true, correct and complete in all respects as of the date hereof and the Completion Date, as though made on
and as of the Completion Date, and the Company will have delivered to the Purchaser a certificate dated the Completion Date, to
the effect that the representations and warranties made by the Company, the Officers, Directors and Shareholders, as applicable,
are true and correct in all material respects, respectively.

 

2.           Performance.
  All of the covenants and undertakings that each of the Company and Shareholders are required to comply with or to perform
at or prior to Completion shall have been complied with and performed in all material respects. Each of the Company and the Shareholders
must have delivered each of the documents required to be delivered by it pursuant to this Agreement.

 

3.           Transaction
Documents.   The Transaction Documents and all other documents necessary or reasonably required to consummate the
transactions contemplated herein, including, without limitation, the sale of the Company Shares and all stock certificates, stock
powers (or indemnities in respect of any such share certificates that are lost) and certified copies of any power of attorney under
which any document required to be delivered under this Section 3, all in form and substance satisfactory to the Purchaser, will
have been executed and delivered to the Purchaser.

 

4.           Shareholders’
Agreement.    Each of the Shareholders shall have entered into the Shareholders’ Agreement.

 

5.           Secretary’s
Certificates.   The Company will have delivered to the Purchaser a certificate from its corporate secretary attaching:
(i) a copy of the articles of incorporation, bylaws and all other incorporation documents, as amended through the Completion Date,
(ii) copies of resolutions duly adopted by the board of directors of the Company and copies of consents of the Shareholders approving
the execution and delivery of this Agreement, the other Transaction Documents and the consummation of the transactions contemplated
hereby and thereby and (iii) good standing certificates (or reasonable foreign equivalent satisfactory to the Purchaser) for the
Company and all Company Subsidiaries in each jurisdiction in which the Company or Company Subsidiary, respectively, is authorized
to conduct business.

 

6.           No
Material Adverse Change.   No event which may be reasonably considered to have a Company Material Adverse Effect
shall have occurred since the date of this Agreement.

  

    	Schedule 2 to Stock Purchase Agreement
Page 1 of 4

    	 

    

  

7.           No
Action.   No Proceeding will be pending or threatened before any Government Entity wherein an unfavorable judgment,
order, decree, stipulation, injunction or charge would: (i) prevent the consummation of the transactions contemplated by the Transaction
Documents, or (ii) cause the transactions contemplated hereby to be rescinded following consummation. No Governmental Entity has
commenced any Proceeding or publicly announced or indicated in writing that it intends to commence any Proceeding that remains
in effect that challenges the sale and purchase of the Company Shares.

 

8.           Outstanding
Shares.   Immediately following Completion, the Purchaser will own not less than one hundred percent (100%) of the
Common Stock free from all Encumbrances.

 

9.           Approvals
and Consents.   The Company (i) will have obtained and (ii) in the case of Shareholders holding Company Shares issued
pursuant to the Plan, shall provide pursuant to Section 7(d)(i) of the Plan, all necessary approvals and consents to carry out
the transaction contemplated hereby, in form and substance reasonably satisfactory to the Purchaser and Purchaser’s Legal
Counsel.

 

10.         Intellectual
Property Consents.   The Company will have obtained all necessary approvals and consents with respect to the Intellectual
Property and Licensed Intellectual Property such that the Intellectual Property and Licensed Intellectual Property shall remain
in full force and effect as though the transactions contemplated hereby shall not have occurred.

 

11.         Due
Diligence.   The Purchaser, Purchaser’s Legal Counsel and any other advisors will be reasonably satisfied with
their due diligence investigation and review of the contents of all documents, records or otherwise of the Company.

 

12.         Directors
and Employees.   The current directors of the Company and Company Subsidiaries shall have resigned, or shall have
tendered resignations and shall have confirmed, in writing, that they have no claim for loss of office. The Company shall have
appointed those individuals as designated by the Purchaser to the board of directors of the Company and Company Subsidiaries. Should
the Purchaser advise any employees (including the Key Employees and Consultants), consultants, independent contractors or other
persons receiving any form of compensation from the Company they desire to retain such person following the Completion Date, that
such person shall have entered into an employment agreement with the Purchaser (or Company, as applicable) in form and substance
reasonably acceptable to the Purchaser, if such person’s position warrants such an agreement. For any persons of the Company
the Purchaser chooses not to retain, including any Key Employee or Consultant, such person shall have agreed in writing: (i) such
employee has no claim for loss of office or employment and (ii) such person, if applicable, shall not exercise any “change
in control” provisions of such person’s employment or consulting agreement.

 

13.         Company
Financial Statements.   The Company will have delivered (a) its unaudited balance sheet and income statement for
each of the fiscal years ended on the

 

    	Schedule 2 to Stock Purchase Agreement
Page 2 of 4

    	 

    

  

Accounts Date, December 31, 2008, December
31, 2007, December 31, 2006 and December 31, 2005, and (b) its unaudited balance sheet and income statement as of the Completion
Date.

 

14.         Organizational
Documents.     The Company shall deliver the articles of incorporation, bylaws, minute books, share registers
and share certificate books (with any unissued share certificates) of the Company and Company Subsidiaries or such equivalent items
in the relevant jurisdiction to the Purchaser on or before the Completion Date.

 

15.         Schedule
of Assets and Liabilities.   The Company shall deliver a schedule of all assets owned in whole or in part by the
Company or any Company Subsidiary and all liabilities, contingencies and liabilities of the Company or any Company Subsidiary as
of the date of execution of this Agreement and as of the Completion Date, each of which shall be reasonably satisfactory to the
Purchaser.

 

16.         Address.
  The address of the registered office of the Company or any Company Subsidiary shall be changed if reasonably requested
by the Purchaser prior to the Completion Date.

 

17.         Common
Stock Register.   The Common Stock register of the Company shall be updated to reflect the sale of the Company Shares.

 

18.         Schedule
6.   Each of the Shareholders shall have executed the signature page to Schedule 6.

 

Schedule 2B: Conditions to Completion
by the Shareholders

 

1.           Representations
and Warranties.   The representations and warranties of the Purchaser shall be true, correct and complete in all
respects as of the date hereof and the Completion Date, as though made on and as of the Completion Date, and the Purchaser will
have delivered to the Shareholders a certificate dated the Completion Date, to the effect that the representations and warranties
made by the Purchaser are true and correct in all material respects.

 

2.           Performance.  
All of the covenants and undertakings the Purchaser is required to comply with or to perform at or prior to Completion shall have
been complied with and performed in all material respects. The Purchaser must have delivered each of the documents required to
be delivered by it pursuant to this Agreement.

 

3.           Transaction
Documents.   The Transaction Documents and all other documents necessary or reasonably required to consummate the
transactions contemplated herein, all in form and substance reasonably satisfactory to the Company will have been executed and
delivered to the Company for distribution to the Shareholders.

 

    	Schedule 2 to Stock Purchase Agreement
Page 3 of 4

    	 

    

  

4.           No
Action.   No Proceeding will be pending or threatened before any Government Entity wherein an unfavorable judgment,
order, decree, stipulation, injunction or charge would: (i) prevent the consummation of the transactions contemplated by the Transaction
Documents, or (ii) cause the transactions contemplated hereby to be rescinded following consummation.

 

Schedule 2C: Non-Waivable Conditions
to Completion

 

1.           Approval
by Purchaser’s Shareholders.    The shareholders of the Purchaser shall have adopted (i) a resolution
to approve an increase in the authorized share capital of the Purchaser in such amount as Purchaser shall deem necessary or advisable
and (ii) a resolution to authorize and approve the issuance of the Initial Shares and delegating to the board of directors of Purchaser
the ability to increase the share capital of the Purchaser to allow for the issuance of the Contingent Shares if and when due.

 

    	Schedule 2 to Stock Purchase Agreement
Page 4 of 4

    	 

    

  

Schedule 3

(Representations and Warranties)

 

Part A: Representations and Warranties
of the Company, its Officers and Directors and with respect to Sections 2.2, 3.4, 3.7, 5.2 and 17.2 of Schedule 3, Part A, the
Shareholders.

 

The following representations
and warranties by the Company, its Officers, Directors and the Shareholders (with respect to 2.2, 3.4, 3.7, 5.2 and 17.2 of this
Schedule 3, Part A) to the Purchaser are qualified, respectively, by those disclosures and exceptions set forth in the Disclosure
Letter and shall be true, correct and complete in all respects as of the date hereof and as of the Completion Date, as though
made on the date hereof and as of the Completion Date. With respect to all of Schedule 3, Part A, the Company and its Officers
and Directors hereby represent and warrant to the Purchaser and with respect to Sections 2.2, 3.4, 3.7, 5.2 and 17.2 of this Schedule
3, Part A, the Shareholders hereby represent and warrant, respectively, as follows (provided, however, that with
respect to any representation or warranty concerning or relating to the Shareholders (or any Shareholder), each Shareholder is
hereby only representing and warranting, on a several basis, as to such Shareholder):

 

1.           Due
Organization and Good Standing.   Each of the Company and each Company Subsidiary is a corporation, limited liability
company or other entity, duly incorporated, formed, or organized, validly existing and in good standing under the Laws of the jurisdiction
of its incorporation, formation, or organization and has all requisite corporate, limited liability, or other organizational power
and authority to own, lease and operate its respective properties and to carry on its respective business as now being conducted.
Each of the Company and each Company Subsidiary is duly qualified or licensed and in good standing to do business in each jurisdiction
in which the character of the property owned, leased or operated by it or the nature of the business conducted by it makes such
qualification or licensing necessary, except where the failure to be so duly qualified or licensed and in good standing would not
reasonably be expected to result in a Company Material Adverse Effect. The Company has heretofore made available to Purchaser accurate
and complete copies of the articles of incorporation and bylaws of the Company (the “Company Organization Documents”)
and the equivalent organizational documents of each of the Company Subsidiaries, each as amended to date and as currently in effect
(the “Company Subsidiary Organization Documents”). None of the Company or any Company Subsidiary is in violation of
any Company Organization Document or Company Subsidiary Organization Document, as the case may be.

 

2.           Authorization;
Binding Agreement.

2.1         The
Company has all requisite corporate power and authority to execute and deliver this Agreement, the Transaction Documents and each
other ancillary agreement related hereto to which it is a party, and to consummate the transactions contemplated hereby and thereby.
The execution and delivery of this Agreement, the Transaction Documents and each other ancillary agreement related hereto to which
it is a party and the consummation of the transactions contemplated hereby and thereby (i) have been duly and validly authorized
by the Company and (ii) no other action on the part of the Company is necessary to authorize the execution and delivery of this
Agreement, the

 

    	Schedule 3 to Stock Purchase Agreement
Page 1 of 17

    	 

    

  

Transaction Documents and each other ancillary
agreement related hereto to which it is a party or to consummate the transactions contemplated hereby and thereby. This Agreement
has been duly and validly executed and delivered by the Company and, assuming the due authorization, execution and delivery of
this Agreement by the Purchaser, constitutes the valid and binding obligation of the Company, enforceable against the Company in
accordance with its terms, except to the extent that enforceability thereof may be limited by applicable bankruptcy, insolvency,
reorganization and moratorium laws and other laws of general application affecting the enforcement of creditors’ rights generally,
and the fact that equitable remedies or relief (including, but not limited to, the remedy of specific performance) are subject
to the discretion of the court from which such relief may be sought (collectively, the “Enforceability Exceptions”).

 

2.2         Each
Shareholder has the legal capacity to execute and deliver this Agreement and the Transaction Documents and to consummate the transactions
contemplated hereby and thereby. This Agreement has been duly and validly executed and delivered by the Shareholder and, assuming
the due authorization, execution and delivery of this Agreement by the Purchaser, constitutes the legal, valid and binding obligation
of each Shareholder, enforceable against each Shareholder in accordance with its terms, except for the Enforceability Exceptions.

 

3.           Capitalization
and Voting Rights.

3.1         The
authorized capital stock of the Company consists of 10,000,000 shares of Common Stock and no shares of preferred stock. As of the
date hereof, (i) 5,390,033 shares of Common Stock are issued and outstanding and no shares of preferred stock are issued and outstanding
and (ii) 4,609,967 shares of Common Stock are authorized but unissued. No other shares of capital stock or other voting securities
of the Company are issued, reserved for issuance or outstanding. All outstanding shares of Common Stock are duly authorized, validly
issued, fully paid and nonassessable and not subject to or issued in violation of any purchase option, right of first refusal,
preemptive right, subscription right or any similar right under any provision of applicable Law, the Company Organization Documents
or any contract to which the Company is a party or by which the Company is bound. The Company has not entered into any other agreements
or commitments to issue any membership interests and has not split, combined or reclassified the Common Stock. The Company directly
or indirectly owns all of the capital stock of, or other equity interests in, the Company Subsidiaries.

 

3.2         There
are no (i) outstanding options, warrants, puts, calls, convertible securities, preemptive or similar rights, (ii) bonds, debentures,
notes or other Indebtedness having general voting rights or that are convertible or exchangeable into securities having such rights,
or (iii) subscriptions or other rights, agreements, arrangements, contracts or commitments of any character, relating to the issued
or unissued membership interests of, or other equity interests in, the Company or any of the Company Subsidiaries or obligating
the Company or any of the Company Subsidiaries to issue, transfer, deliver or sell or cause to be issued, transferred, delivered,
sold or repurchased any options or membership interests of, or other equity interest in, the Company or any of the Company

 

    	Schedule 3 to Stock Purchase Agreement
Page 2 of 17

    	 

    

  

Subsidiaries or securities convertible
into or exchangeable for such shares or equity interests, or obligating any of the Company Subsidiaries to grant, extend or enter
into any such option, warrant, call, subscription or other right, agreement, arrangement or commitment for such equity interest.
There are no outstanding obligations of the Company or any Company Subsidiaries to repurchase, redeem or otherwise acquire any
membership interests, capital stock of, or other equity interests in, the Company or any of the Company Subsidiaries or to provide
funds to make any investment (in the form of a loan, capital contribution or otherwise) in any other entity.

 

3.3         There
are no stockholders or members agreements, voting trusts or other agreements or understandings to which the Company or any Company
Subsidiary is a party with respect to the voting of the Company Shares or the capital stock or equity interests of any Company
Subsidiary.

 

3.4         Each
of the Shareholders holds of record and owns beneficially the number of shares of Common Stock set forth next to such Shareholder’s
name in Schedule 1 free and clear of any restrictions on transfer, security interests, options, warrants, purchase rights, contracts,
commitments, equities, claims, demands or Encumbrances and all of the Shareholders in the aggregate own 100% of the Company Common
Stock. None of the Shareholders is a party to any option, warrant, purchase right, or other contract or commitment that could require
one or more Shareholders to sell, transfer or otherwise dispose of any Common Stock (other than this Agreement) or is a party to
any voting trust, proxy, or other agreement or understanding with respect to the voting of any of the Common Stock.

 

3.5         No
Indebtedness of the Company or any of the Company Subsidiaries contains any restriction upon (i) the prepayment of any of such
Indebtedness, (ii) the incurrence of Indebtedness by the Company or any of the Company Subsidiaries, or (iii) the ability of the
Company or any of the Company Subsidiaries to grant any Encumbrance on its properties or assets (including the Intellectual Property
and Licensed Intellectual Property).

 

3.6         From
inception through the date hereof, the Company has not declared or paid any distribution or dividend in and has not authorized
or repurchased, redeemed or otherwise acquired any Common Stock of the Company.

 

3.7         The
Shareholders are sophisticated persons with respect to the Common Stock, have adequate information concerning the business and
financial condition of the Purchaser and their respective assets, have been given the information necessary to make an informed
decision regarding this Agreement, the Transaction Documents and the transactions contemplated hereby and have independently made
their analysis and decision to enter into and consummate this Agreement based upon such information the Shareholders deem appropriate.
Notwithstanding the foregoing, no information or knowledge obtained by the Shareholders as described herein will affect or be deemed
to modify any representation or warranty contained herein or the conditions to the obligations pursuant to this Agreement.

 

    	Schedule 3 to Stock Purchase Agreement
Page 3 of 17

    	 

    

  

4.           Subsidiaries.
  Schedule 4 sets forth a true, complete and correct list of each of the Company Subsidiaries and their respective jurisdictions
of incorporation, formation or organization. All of the capital stock and other equity interests of the Company Subsidiaries are
owned, directly or indirectly, by the Company free and clear of any Encumbrance (other than any restriction under the Securities
Act, or any state “blue sky” securities Laws or the foreign equivalent) with respect thereto. All of the outstanding
shares of capital stock or other equity interests in each of the Company Subsidiaries that is a corporation are duly authorized,
validly issued, fully paid and non-assessable, and with respect to the Company Subsidiaries that are limited liability companies,
are duly authorized, validly issued, fully paid and non-assessable and were issued free of preemptive rights and were not issued
in material violation of any applicable foreign, federal or state securities Laws. Neither the Company nor any Company Subsidiary
owns, directly or indirectly, any shares of capital stock or other equity or voting interests in (including any securities exercisable
or exchangeable for or convertible into capital stock or other equity or voting interests in) any other person other than capital
stock or other equity interest of the Company Subsidiaries owned by the Company or another Company Subsidiary.

 

5.           Litigation.

5.1         There
is no private, regulatory or governmental inquiry, action, suit, proceeding, litigation, claim, arbitration or investigation pending
before any Governmental Entity of competent jurisdiction (each, an “Action”) or threatened against the Company, any
of the Company Subsidiaries or any of their respective properties, rights or assets or any of their respective managers, officers
or directors (in their capacities as such) that would reasonably be expected to result in a Company Material Adverse Effect. There
is no decree, directive, order, writ, judgment, stipulation, determination, decision, award, injunction, temporary restraining
order, cease and desist order or other order by, or any supervisory agreement or memorandum of understanding with any Governmental
Entity (each, an “Order”) binding against the Company, any of the Company Subsidiaries or any of their respective properties,
rights or assets or any of their respective managers, officers or directors (in their capacities as such) that would prohibit,
prevent, enjoin, restrict or alter or delay any of the transactions contemplated by this Agreement, or that would reasonably be
expected to result in a Company Material Adverse Effect. The Company and the Company Subsidiaries are in material compliance with
all Orders. There is no material Action that the Company or any of the Company Subsidiaries has pending against other parties.

 

5.2         There
is no Action pending or threatened against such Shareholder that would reasonably be expected to, individually or in the aggregate,
prevent or delay the consummation of the transactions contemplated by this Agreement. There is no Order binding against such Shareholder
that would prohibit, prevent, enjoin, restrict or materially alter or delay any of the transactions contemplated by this Agreement.

 

    	Schedule 3 to Stock Purchase Agreement
Page 4 of 17

    	 

    

  

6.           Accounts;
Management Accounts.

6.1         True
and correct copies of the Accounts as of the Accounts Date are attached hereto on Schedule 7. The Accounts in all material respects
accurately reflect the Company’s books and records as of the times and for the periods referred to therein. The Management
Accounts will, as of the Completion Date, (i) in all material respects accurately reflect the Company’s books and records
as of the times and for the periods referred to therein, and (ii) fairly present in all material respects the consolidated financial
position of the Company as of the respective dates thereof and the consolidated results of the Company’s operations and cash
flows for the periods indicated.

 

6.2         The
Company has disclosed to the Purchaser and its advisors any material fraud that involves management or other employees who have
a significant role in the Company’s internal controls over financial reporting.

 

6.3         None
of the Company, any Company Subsidiary, or any manager, director, officer, auditor or accountant of the Company or any Company
Subsidiary or any employee of the Company or any Company Subsidiary has received any written complaint, allegation, assertion or
claim from any Governmental Entity regarding the accounting or auditing practices, procedures, methodologies or methods of the
Company or any Company Subsidiary or their respective internal accounting controls, including any complaint, allegation, assertion
or claim that the Company or any Company Subsidiary has engaged in questionable accounting or auditing practices. No Key Employee
has received written notice from any Governmental Entity or any person of any material violation of consumer protection, insurance
or securities Laws by the Company, any Company Subsidiary or any of their respective officers, managers, directors, employees or
agents.

 

7.           Employee
Benefit Plans.

7.1         The
Disclosure Letter lists, with respect to the Company and the Company Subsidiaries, (i) all employee benefit plans (as defined in
Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and their foreign counterparts),
(ii) material loans from the Company to managers, officers and directors other than advances for expense reimbursements incurred
in the ordinary course of business, (iii) any securities option, securities stock purchase, phantom securities, securities appreciation
right, equity-related, supplemental retirement, severance, sabbatical, medical, dental, vision care, disability, employee relocation,
cafeteria benefit (Code section 125) or dependent care (Code Section 129), life insurance or accident insurance plans, programs,
agreements or arrangements, (iv) all bonus, pension, retirement, profit sharing, savings, deferred compensation or incentive plans,
programs, policies, agreements or arrangements, (v) other material fringe, perquisite, or employee benefit plans, programs, policies,
agreements or arrangements, and (vi) any current or former employment, change of control, retention or executive compensation,
termination or severance plans, programs, policies, collective bargaining, agreements or arrangements, written or otherwise, as
to which material unsatisfied liabilities or obligations, contingent or otherwise, remain for the benefit of, or relating to, any
present or former employee, consultant, manager or director, or which could reasonably be expected to have any material liabilities
or obligations (together, the “Company Benefit

 

    	Schedule 3 to Stock Purchase Agreement
Page 5 of 17

    	 

    

  

Plans”). The term Company Benefit
Plans also includes all benefit plans subject to Title IV of ERISA in connection with which any trade or business (whether or not
incorporated) that is treated as a single employer with the Company and the Company Subsidiaries within the meaning of Section
414(b), (c), (m) or (o) of the Code (a “Company ERISA Affiliate”) has any liability.

 

7.2         Other
than as would not reasonably be expected to result in a Company Material Adverse Effect, (i) there has been no “prohibited
transaction,” as such term is defined in Section 406 of ERISA and Section 4975 of the Code, by the Company or by any trusts
created thereunder, any trustee or administrator thereof or any other person, with respect to any Company Benefit Plan, (ii) each
Company Benefit Plan has been administered in material accordance with its terms and in material compliance with the requirements
prescribed by any and all applicable Laws (including ERISA and the Code), (iii) the Company and each Company ERISA Affiliate have
performed in all material respects all obligations required to be performed by them under, are not in any respect in default under
or violation of, and have no Knowledge of any default or violation by any other party to, any of the Company Benefit Plans that
are subject to Title IV of ERISA, (iv) all contributions and premiums required to be made by the Company or any Company ERISA Affiliate
to any Company Benefit Plan subject to Title IV of ERISA have been made on or before their due dates, including any legally permitted
extensions. Except with respect to claims for benefits in the ordinary course, no Action has been brought, or is threatened, against
or with respect to any such Company Benefit Plan, including any audit or inquiry by the Internal Revenue Service, United States
Department of Labor or other Governmental Entity (other than as would not result in a Company Material Adverse Effect). Each Company
Benefit Plan that is a “nonqualified deferred compensation plan” within the meaning of Section 409A of the Code and
any awards thereunder, in each case that is subject to Section 409A of the Code, has been operated in good faith compliance, in
all material respects, with Section 409A of the Code since January 1, 2005.

 

7.3         The
consummation of the transactions contemplated by this Agreement and any ancillary agreement related hereto to which the Company
is a party, will not, either alone or in combination with any other event or events, (i) entitle any current or former employee,
manager, director or consultant of the Company or any of the Company Subsidiaries to any payment of severance pay, golden parachute
payments, or bonuses, (ii) accelerate, forgive indebtedness, vest, distribute, or increase benefits or obligation to fund benefits
with respect to any employee or director of the Company or any of the Company Subsidiaries, or (iii) accelerate the time of payment
or vesting of options to purchase securities of the Company, or increase the amount of compensation due any such employee, director
or consultant.

None of the Company Benefit Plans contains
any provision requiring a gross-up pursuant to Section 280G or 409A of the Code or similar Tax provisions.

 

7.4         No
Company Benefit Plan maintained by the Company or any of the Company Subsidiaries provides material benefits, including death or
medical benefits (whether or not insured), with respect to current or former employees of the Company or any of the

 

    	Schedule 3 to Stock Purchase Agreement
Page 6 of 17

    	 

    

  

Company Subsidiaries after termination
of employment (other than (i) coverage mandated by applicable Laws, (ii) death benefits or retirement benefits under any “employee
pension benefit plan,” as that term is defined in Section 3(2) of ERISA, or (iii) benefits, the full direct cost of which
is borne by the current or former employee (or beneficiary thereof)).

 

7.5         Neither
the Company nor any Company ERISA Affiliate has any liability with respect to any (i) employee pension benefit plan that is subject
to Part 3 of Subtitle B of Title I of ERISA, Title IV of ERISA or Section 412 of the Code, (ii) “multiemployer plan”
as defined in Section 3(37) of ERISA or (iii) “multiple employer plan” within the meaning of Sections 4063 and 4064
of ERISA or Section 413(c) of the Code.

 

8            Taxes
and Returns.

8.1         The
Company has or will have timely filed, or caused to be timely filed, all material federal, state, local and foreign Tax returns
and reports required to be filed by it or the Company Subsidiaries (taking into account all available extensions) (collectively,
“Tax Returns”), which such Tax Returns are true, accurate, correct and complete, and has paid, collected or withheld,
or caused to be paid, collected or withheld set forth on such Tax Returns, all material Taxes required to be paid, collected or
withheld. There are no claims, assessments, audits, examinations, investigations or other proceedings pending against the Company
or any of the Company Subsidiaries in respect of any Tax, and neither the Company nor any of the Company Subsidiaries has been
notified in writing of any proposed Tax claims or assessments against the Company or any of the Company Subsidiaries. There are
no material liens with respect to any Taxes upon any of the Company’s or the Company Subsidiaries’ assets, other than
(i) Taxes, the payment of which is not yet due, or (ii) Taxes or charges being contested in good faith by appropriate proceedings.
Neither the Company nor any of the Company Subsidiaries has any outstanding waivers or extensions of any applicable statute of
limitations to assess any material amount of Taxes. There are no outstanding requests by the Company or any of the Company Subsidiaries
for any extension of time within which to file any Tax Return or within which to pay any Taxes shown to be due on any Tax Return.
There are no Encumbrances for material amounts of Taxes on the assets of the Company or any of the Company Subsidiaries, except
for statutory liens for current Taxes not yet due and payable.

 

8.2         Neither
the Company nor any of the Company Subsidiaries has made any change in accounting method or received a ruling from, or signed an
agreement with, any taxing authority that would reasonably be expected to result in a Company Material Adverse Effect following
Completion.

 

8.3         As
of the date hereof, neither the Company nor any of the Company Subsidiaries is being audited by any taxing authority or has been
notified by any Tax authority that any such audit is contemplated or pending.

 

    	Schedule 3 to Stock Purchase Agreement
Page 7 of 17

    	 

    

  

8.4         Neither
the Company nor any of the Company Subsidiaries participated in, or sold, distributed or otherwise promoted, any “reportable
transaction,” as defined in Treasury Regulation section 1.6011-4.

 

8.5         Neither
the Company nor any of the Company Subsidiaries have (i) changed any Tax accounting methods, policies or procedures except as required
by a change in Law, (ii) made, revoked, or amended any material Tax election, (iii) filed any amended Tax Returns or claim for
refund, or (iv) entered into any closing agreement affecting or otherwise settled or compromised any material Tax liability or
refund.

 

8.6         The
Company and the Company Subsidiaries have withheld and paid all Taxes required to have been withheld and paid in connection with
amounts paid or owing to any employee, independent contractor, consultant, creditor, stockholder, or other third party.

 

9            Title
to Properties; Assets.

9.1         The
Disclosure Letter contains a correct and complete list of all real property and interests in real property leased or subleased
by the Company or any of the Company Subsidiaries from or to any person (collectively, the “Company Real Property”).
The Disclosure Letter contains, with respect to each of the Company Real Properties, all existing leases, subleases, licenses or
other occupancy contracts to which the Company or any of the Company Subsidiaries is a party or by which the Company or any of
the Company Subsidiaries is bound, and all amendments, modifications, extensions and supplements thereto (collectively, the “Tenant
Leases”), the terms of which have been complied with by the Company and any Company Subsidiary in all material respects.
The Company Real Property set forth in the Disclosure Letter comprises all of the real property necessary and/or currently used
in the operations of the business of the Company and the Company Subsidiaries. The Company does not own any real property. The
Company or a Company Subsidiary has good and valid title to, a valid leasehold interest in, or valid license to use, all of the
material personal property, assets and rights used by them in the operation of their respective businesses, free and clear of all
Encumbrances.

 

9.2         A
correct and complete copy of each Tenant Lease has been made available to Purchaser prior to the date hereof. The Company or the
Company Subsidiary’s interest in each of the Tenant Leases is free and clear of ail Encumbrances and each of the Tenant Leases
is in full force and effect. Neither the Company nor any of the Company Subsidiaries is in breach of or in default under (with
or without notice or lapse of time or both), in any material respect, any of the Tenant Leases. The Company and the Company Subsidiaries
enjoy peaceful and undisturbed possession under all such Tenant Leases, have not received notice of any material default, delinquency
or breach on the part of the Company or any Company Subsidiary.

 

9.3         Each
asset included in the Accounts or acquired by the Company or any Company Subsidiary since the Accounts Date (other than assets
disposed of in the ordinary course of business or which are the subject matter of operating or finance, property or capital leases)
is:

 

    	Schedule 3 to Stock Purchase Agreement
Page 8 of 17

    	 

    

  

(a)          legally
and beneficially owned solely by the Company or a Company Subsidiary free from any Encumbrance (other than retention of title claims
or liens arising in the ordinary course of business); and

 (b)          where
capable of possession, in the possession or under the control of the Company or a Company Subsidiary.

 

9.4         The
Company and Company Subsidiaries own or have the right to use each asset reasonably necessary for the effective operation of the
business as the same is conducted in the ordinary course as at the date of this Agreement, other than assets which may be obtained
from or replaced by multiple commercial sources.

 

9.5         The
rights, Company Real Property, and assets (including Intellectual Property and Licensed Intellectual Property) of each of the Company
and Company Subsidiary and rights of the Purchaser pursuant to this Agreement, include all rights, Company Real Property, assets,
facilities and services which are reasonably necessary for carrying on the business in the places and substantially in the manner
in which it is carried on as at the date of this Agreement.

 

10.         Employee
Matters.

10.1       There
are no Actions pending or threatened involving the Company or any Company Subsidiary and any of their respective employees or former
employees (with respect to their status as an employee or former employee, as applicable) including any harassment, discrimination,
retaliatory act or similar claim. The Company and the Company Subsidiaries (i) are in compliance in all material respects with
all applicable Laws respecting employment and employment practices, terms and conditions of employment, health and safety and wages
and hours, including Laws relating to discrimination, disability, labor relations, hours of work, payment of wages and overtime
wages, pay equity, immigration, workers compensation, working conditions, employee scheduling, occupational safety and health,
family and medical leave, and employee terminations, and have not received written notice, or any other form of notice, that there
is any Action involving unfair labor practices against the Company or any of the Company Subsidiaries pending, (ii) are not liable
for any material arrears of wages or any material penalty for failure to comply with any of the foregoing, and (iii) are not liable
for any material payment to any trust to any Governmental Entity, with respect to unemployment compensation benefits, Taxes, social
security or other benefits or obligations for employees, independent contractors or consultants (other than routine payments to
be made in the ordinary course of business and consistent with past practice).

 

10.2       The
Disclosure Letter contains accurate details as of the date hereof of:

(a)          the
total number of employees of the Company and the Company Subsidiaries as at March 31, 2010 and the applicable salary, period of
continuous employment, work location, notice period, bonus payments, age and grade together with a summary description of each
benefit whether provided on a contractual or discretionary basis, for each such employee;

 

    	Schedule 3 to Stock Purchase Agreement
Page 9 of 17

    	 

    

  

(b)          the
employment contract of each Key Employee and Consultant or any other employees of the Company with an employment agreement;

(c)          all
consultancy agreements under which services are provided to the Company or any Company Subsidiary;

(d)          the
standard terms and conditions of employment, any employee handbook or similar document issued by or on behalf of the Company and
Company Subsidiaries (whether issued in paper or electronic form).

 

10.3       Neither
the Company nor any Company Subsidiary has provided or agreed to provide a gratuitous payment or benefit to a current or former
director, officer, employee, worker or consultant or to any of their dependents.

 

10.4       There
are no work councils or labor unions formed in the Company or Company Subsidiaries.

 

11.         Environmental
Matters.

11.1       Neither
the Company nor any of the Company Subsidiaries is the subject of any federal, state, local or foreign Order, judgment or claim,
and neither the Company nor any of the Company Subsidiaries has received any notice or claim, or entered into any negotiations
or agreements with any person, that would impose a material liability or obligation under any Environmental Law. The Company and
the Company Subsidiaries are in material compliance with all applicable Environmental Laws;

 

11.2       Neither
the Company nor any of the Company Subsidiaries has manufactured, treated, stored, disposed of, arranged for or permitted the disposal
of, generated, handled or released any Hazardous Substance, or owned or operated any property or facility, in a manner that has
given or would reasonably be expected to give rise to any material liability under applicable Environmental Laws; and

 

11.3       Each
of the Company and the Company Subsidiaries holds and is in material compliance with all permits required to conduct its business
and operations under all applicable Environmental Laws.

 

11.4       None
of the Company, any Company Subsidiary or any of their respective properties is subject to any Order, judgment or written claim
asserted or arising under any Environmental Law.

 

12.         Transactions
with Affiliates.   Other than (i) for payment of salary for services rendered, (ii) reimbursement for reasonable
expenses incurred on behalf of the Company or any Company Subsidiary, (iii) for other employee benefits made generally available
to all employees, (iv) with respect to any capital stock or other securities of the Company or any Company Subsidiary or such person’s
employment with the Company or any Company Subsidiary, there are no contracts or arrangements that are in existence as of the date
of this Agreement under which there are any material existing or future liabilities or obligations between the Company or any of
the Company Subsidiaries, on the one

 

    	Schedule 3 to Stock Purchase Agreement
Page 10 of 17

    	 

    

  

hand, and, on the other hand, any present
manager, officer or director of either the Company or any of the Company Subsidiaries or any Affiliate.

 

13.         Insurance.
  The Disclosure Letter sets forth a correct and complete list of all insurance policies issued in favor of the Company
or any Company Subsidiary, or pursuant to which the Company or any Company Subsidiary is a named insured or otherwise a beneficiary.
With respect to each such insurance policy, (i) the policy is in full force and effect and all premiums due thereon have been paid
and (ii) neither the Company nor any Company Subsidiary is in any material respect, in breach of or default under, and neither
the Company nor any Company Subsidiary has taken any action or failed to take any action which, with notice or the lapse of time
or both, would constitute such a breach or default, or permit termination or modification of, any such policy.

 

14.         Books
and Records.   All of the books and records of the Company and the Company Subsidiaries are complete and accurate
in all material respects and have been maintained in the ordinary course and in accordance with all applicable Laws.

 

15.         Insolvency.  
Neither the Company nor any Company Subsidiary has received written notice of, any insolvency Proceedings having commenced in relation
to the Company or Company Subsidiary.

 

16.         Compliance
with Statutes; Rules & Regulations.   The Company and the Company Subsidiaries have materially complied with,
are not in material violation of, and have not received any written notices of violation from a Governmental Entity with respect
to, any U.S. Laws, or, to its Knowledge, foreign or EU national or local statute, law or regulation applicable to it, including
without limitation all statutes, rules, or regulations relating to the ownership, testing, development, manufacture, packaging,
processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any
product or product candidate manufactured or distributed by the Company (or any Company Subsidiary), or any license, certificate,
approval, clearance, authorization, permit, supplement or amendment required pursuant thereto (“Authorizations”). The
Company and the Company Subsidiaries possesses all material Authorizations necessary for its existing products and such material
Authorizations are in full force and effect. The Company and Company Subsidiaries are in compliance in all material respects with
all existing Authorizations, including, but not limited to, all laws, statutes, rules, regulations, or orders administered, issued
or enforced by the Federal Food and Drug Administration (the “FDA”) or any other federal or foreign governmental authority
having authority over the Company, any Company Subsidiary or any of its products. The Company has not received from the FDA or
any other similar authority any notice of adverse findings, regulatory letters, notices of violations, warning letters, criminal
proceeding notices under Section 305 of the Federal Food, Drug, and Cosmetic Act, or other similar communication from the FDA or
similar authority alleging or asserting material noncompliance with any Laws or Authorizations, and there have been no seizures
conducted or threatened by the FDA or other similar authority. The Company has not received notice of any claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other similar action from any Governmental Entity alleging

 

    	Schedule 3 to Stock Purchase Agreement
Page 11 of 17

    	 

    

  

that any product operation or activity
is in material violation of any Laws or Authorizations and has no Knowledge that any such Governmental Entity is considering any
such claim, litigation, arbitration, action, suit, investigation or proceeding. Each regulatory submission by the Company or Company
Subsidiaries has been filed, cleared and maintained in compliance in all material respects with all Laws and Authorizations, including
without limitation applicable federal statutes, rules, regulations or orders administered or promulgated by the FDA or other Governmental
Entity, and all laboratory and clinical studies, and tests that the Company or Company Subsidiaries have conducted and are conducting
to demonstrate the safety and efficacy of its products are in all material respects in compliance with accepted professional scientific
standards and all Laws and Authorizations in all material respects. No filing or submission by the Company or Company Subsidiaries
to the FDA or any other Governmental Entity contains any material omission or material false information or presents data and results
from the studies in any manner other than fair, accurate, and complete presentation. The Company and Company Subsidiaries are not
aware, directly or indirectly of any other studies, tests, trials, presentations, publications or other information that could
reasonably call into question the validity, completeness, or accuracy of any study, test, trial, results or data relating to the
Company’s and Company Subsidiaries’ products or product candidates. The Company and Company Subsidiaries have not,
nor, to the Company’s Knowledge, has any sponsor, received any notices or correspondence from any Governmental Entity (including,
but not limited to, the FDA) requiring suspension of any studies, tests, or clinical trials conducted by or on behalf of the Company
or Company Subsidiaries. The Company and Company Subsidiaries do not have Knowledge of any facts which are reasonably likely to
cause (i) the nonapproval, non-clearance or withdrawal of any products of the Company or any Company Subsidiary, or (ii) a suspension
or revocation of any of the Company’s Authorizations.

 

17.         No
Violations.

17.1       The
execution and delivery by the Company of this Agreement and each other ancillary agreement related hereto to which it is a party,
the consummation by the Company of the transactions contemplated hereby and thereby, and compliance by the Company with any of
the provisions hereof and thereof, will not, (i) conflict with or violate any provision of any Company Organization Document or
Company Subsidiary Organization Document, (ii) require any consent under or result in a violation or breach of, or constitute (with
or without due notice or lapse of time or both) a default (or give rise to any right of termination, cancellation, amendment or
acceleration) under, any Company Material Contract (as defined in Schedule 3), (iii) result (immediately or with the passage of
time or otherwise) in the creation or imposition of any Encumbrances upon any of the properties, rights or assets of the Company
or any of the Company Subsidiaries, or (iv) subject to obtaining the consents from Governmental Entities (including the FDA), conflict
with or violate any foreign, federal, state or local Order, statute, law, rule, regulation, ordinance, principle of common law,
constitution, treaty enacted, or any writ, arbitration award, injunction, directive, judgment, or decree, promulgated, issued,
enforced or entered by any Governmental Entity to which the Company or any of the Company Subsidiaries or any of their respective
assets or properties is subject, except, in the case of Sections (ii), (iii) and (iv) above, for any

 

    	Schedule 3 to Stock Purchase Agreement
Page 12 of 17

    	 

    

  

deviations from any of the foregoing that
would not reasonably be expected to result in a Company Material Adverse Effect.

 

17.2       The
execution and delivery by the Shareholders of this Agreement and the Transaction Documents, the consummation by the Shareholders
of the transactions contemplated hereby, and compliance by the Shareholders with any of the provisions hereof, will not (i) result
(immediately or with the passage of time or otherwise) in the creation or imposition of any Encumbrance or restriction under the
“blue sky” or securities Laws of any jurisdiction outside the United States) with respect to the Common Stock owned
by the Shareholders, or (ii) conflict with, contravene or violate any Law, including any “blue sky” securities Laws
of any jurisdiction outside the United States, applicable to the Shareholders, except, with respect to Section (ii), for any deviations
from any of the foregoing that would not reasonably be expected to result in a Company Material Adverse Effect.

 

18.         Absence
of Undisclosed Liabilities.    From inception through the date hereof, neither the Company nor any Company Subsidiary
has incurred any liabilities or obligations of the type required to be reflected on a balance sheet that is not adequately reflected
or reserved on or provided for in the Account or Management Account, other than liabilities of the type that have been incurred
in the ordinary course of business consistent with past practice.

 

19.         Restrictions
on Business Activities.   There is no Order binding upon the Company or any of the Company Subsidiaries that has
or could reasonably be expected to have the effect of prohibiting, preventing, restricting or impairing in any respect, any business
practice of the Company or any of the Company Subsidiaries as their businesses are currently conducted, any acquisition of property
by the Company or any of the Company Subsidiaries, the conduct of business by the Company or any of the Company Subsidiaries as
currently conducted, or the ability of the Company or any of the Company Subsidiaries from engaging in business as currently conducted
or from competing with other parties, except for such Orders that would not reasonably be expected to result in a Company Material
Adverse Effect.

 

20.         Material
Contracts.    (a)    The Disclosure Letter sets forth a list of, and the Company has
made available to Purchaser, true, correct and complete copies of, each material written contract, agreement, commitment, arrangement,
lease, license, permit or plan and each other instrument (other than this Agreement or any ancillary agreement contemplated hereby)
currently in effect to which the Company or any Company Subsidiary is a party or by which the Company, any Company Subsidiary,
or any of their respective properties or assets are bound or affected as of the date hereof (each, a “Company Material Contract”)
that:

 

(i)          contains
covenants that materially limit the ability of the Company or any Company Subsidiary: (A) to compete in any line of business or
with any person or in any geographic area or to sell, or provide any service or product, including

 

    	Schedule 3 to Stock Purchase Agreement
Page 13 of 17

    	 

    

  

any non-competition covenants, exclusivity
restrictions, rights of first refusal or most-favored pricing Sections or (B) to purchase or acquire an interest in any other
entity, except, in each case, for any such contract that may be canceled without any penalty or other liability to the Company
or any Company Subsidiary upon notice of sixty (60) days or less;

 

(ii)         involves
any joint venture, partnership, limited liability company or other similar agreement or arrangement relating to the formation,
creation, operation, management or control of any partnership or joint venture that is material to the business of the Company
and the Company Subsidiaries, taken as a whole;

 

(iii)        evidences
Indebtedness (whether incurred, assumed, guaranteed or secured by any asset) having an outstanding principal amount in excess
of $20,000;

 

(iv)        by
its terms calls for aggregate payments by the Company or the Company Subsidiaries under such contract of more than $20,000 per
year;

 

(v)         with
respect to any material acquisition of another person, pursuant to which the Company or any Company Subsidiary has (A) any continuing
indemnification obligations or (B) any “earn out” or other contingent payment obligations;

 

(vi)        other
than in the ordinary course of business, obligates the Company or any Company Subsidiary to provide continuing indemnification
or a guarantee of obligations after the date hereof;

 

(vii)       is
between the Company or any Company Subsidiary and any of their respective managers, directors or executive officers that cannot
be cancelled by the Company (or the applicable Company Subsidiary) with sixty (60) days’ notice without material liability,
penalty or premium;

 

(viii)      other
than in the ordinary course of business, obligates the Company or any Company Subsidiary to make any capital commitment or expenditure
in excess of $20,000 (including pursuant to any joint venture);

 

(ix)         provides
for any standstill arrangements.

 

(b)          Each
Company Material Contract: (i) is valid and binding and enforceable in all respects against the Company or the Company Subsidiary
party thereto (subject to Enforceability Exceptions) and the other party thereto, and other than such contracts that have expired
by their terms, in full force and effect; (ii) the consummation of the transactions contemplated by the Agreement and the Transaction
Documents will not affect the terms, validity or enforceability of the Company Material Contract against the Purchaser and the
other party thereto; (iii) neither the Company nor any Company Subsidiary is in breach or default in any respect, and no event
has occurred that with the passage of time or giving of notice or both would constitute a breach or default by the

 

    	Schedule 3 to Stock Purchase Agreement
Page 14 of 17

    	 

    

  

Company or any Company Subsidiary, or permit
termination or acceleration by the other party thereto, under such Company Material Contract; (iv) to the Company’s Knowledge,
no other party to such Company Material Contract is in breach or default in any respect, and no event has occurred that with the
passage of time or giving of notice or both would constitute such a breach or default by such other party, or permit termination
or acceleration by the Company or any of the Company Subsidiaries, under such Company Material Contract, and (v) no other party
to such Company Material Contract has notified the Company or any Company Subsidiary in writing that it is terminating or considering
terminating the handling of its business by the Company or any Company Subsidiary or in respect of any particular product, project
or service of the Company, or is planning to materially reduce its future business with the Company or any Company Subsidiary in
any manner except, with respect to each of Sections (i) through (v), for any deviations from any of the foregoing or that would
not reasonably be expected to result in a Company Material Adverse Effect.

 

21.         Intellectual
Property.    The Disclosure Letter contains a list of: (i) all registered Intellectual Property and Intellectual
Property that is the subject of a pending application for registration, and material unregistered Intellectual Property, in each
case that is, owned by the Company or any of the Company Subsidiaries (“Company Intellectual Property”); and (ii) all
material Intellectual Property that is licensed to the Company or any of the Company Subsidiaries (“Licensed Intellectual
Property”). Except where failure to own, license or otherwise possess such rights has not had and would not reasonably be
expected to result in a Company Material Adverse Effect, each of the Company and the Company Subsidiaries (x) has all right, title
and interest in and to all Company Intellectual Property owned by it, free and clear of all Encumbrances, (y) has valid rights
in and to all of its Licensed Intellectual Property and (z) has made all maintenance (or similar) payments required by (A) the
Company or Company Subsidiary or (B) any contract or agreement, to maintain in good standing with the applicable Government Entity
the Company Intellectual Property and the Licensed Intellectual Property. Neither the Company nor any of the Company Subsidiaries
has received any notice alleging that it has infringed, diluted or misappropriated, or, by conducting its business as currently
conducted, would infringe, dilute or misappropriate, the Intellectual Property rights of any person, and to the Knowledge of the
Company there is no valid basis for any such allegation. Neither the execution nor delivery of this Agreement or the Transaction
Documents nor the consummation of the transactions contemplated hereby or thereby will impair or materially alter the Company’s
or any Company Subsidiary’s rights to any Company Intellectual Property or Licensed Intellectual Property. To the Company’s
Knowledge, all of the rights within the Company Intellectual Property and the license rights to the Licensed Intellectual Property
are valid, enforceable and subsisting and there is no Action that is pending or, to the Company’s Knowledge, threatened that
challenges the rights of the Company or any of the Company Subsidiaries in respect of any Company Intellectual Property or Licensed
Intellectual Property or the validity, enforceability or effectiveness thereof. The Company Intellectual Property and the Licensed
Intellectual Property constitute all material Intellectual Property owned by or licensed to the Company or the Company Subsidiaries
and used in or necessary for the operation by the Company and the Company Subsidiaries of their respective businesses

 

    	Schedule 3 to Stock Purchase Agreement
Page 15 of 17

    	 

    

  

as currently conducted. To the Knowledge
of the Company, neither the Company nor any of the Company Subsidiaries is in breach or default in any material respect (or would
with the giving of notice or lapse of time or both be in such breach or default) under any license to use any of the Licensed Intellectual
Property.

 

22.         Accounts
Receivable.    The Disclosure Letter sets forth as of March 31, 2010 (and which shall be updated as of the Completion
Date, if applicable) all accounts, notes and other receivables, whether or not accrued, and whether or not billed, of the Company
and/ or the Company Subsidiaries (the “Accounts Receivable”). All Accounts Receivable arose in the ordinary course
of business and represent bona fide revenues of the Company and/ or the Company Subsidiaries arising from their respective businesses.
None of the Accounts Receivable are subject to any right of recourse, defense, deduction, return of goods, counterclaim, offset,
or set off on the part of the obligor.

 

Part B: Representations and Warranties
of the Purchaser

 

1.           Organization
and Good Standing.   The Purchaser is a corporation duly organized, validly existing and in good standing under the
laws of France and has all requisite corporate power to own, lease and operate its property and to carry on its business as now
being conducted and is duly qualified or licensed to do business.

 

2.           Authority.
  The Purchaser has the requisite right, corporate power and authority to enter into and perform this Agreement and any
other Transaction Document. The execution and delivery of the Transaction Documents and the consummation of the transactions contemplated
thereby have been duly authorized by all necessary corporate action on the part of the Purchaser. The Transaction Documents have
been duly executed and delivered by the Purchaser and constitute the legal, valid and binding obligations of the Purchaser, enforceable
against the Purchaser in accordance with their terms, except to the extent that enforceability may be limited by applicable bankruptcy,
reorganization, insolvency, moratorium or other Laws affecting the enforcement of creditors’ rights generally and by general
principles of equity.

 

3.           Non-Contravention.
  The execution and delivery of, and the performance by the Purchaser of its obligations under this Transaction Documents
will not (i) result in a material breach of any provision of the articles of incorporation or the bylaws of the Purchaser, (ii)
result in a material breach of, or constitute a default under, any instrument to which the Purchaser is a party or by which the
Purchaser is bound, (iii) result in a material breach of any permit, concession, license, ordinance, rule or regulation, order,
judgment or decree of any court or Governmental Entity or agency to which the Purchaser is a party, by which the Purchaser is bound
or which is applicable to the Purchaser, (iv) result in a material breach of any Laws or regulations applicable to the Purchaser;
or (v) require the consent of its shareholders or of any other person (without prejudice with respect to the provision of Schedule
2C).

 

4.           Stock
Authorization.    Subject to Schedule 2C and with the exception of any provision of the by-laws of the Purchaser,
the Shareholder Agreement or this Agreement

  

    	Schedule 3 to Stock Purchase Agreement
Page 16 of 17

    	 

    

  

to the contrary, the Initial Shares shall
be validly authorized and approved for issuance upon Completion, fully paid and non-assessable, free from any and all Encumbrances
and issued in compliance with all applicable French Laws. Specifically with respect to the Contingent Shares, such approvals and
authorizations shall remain in full force and effect for not less than twenty-six (26) months following the Completion Date

 

5.           Stockholder
Rights.   The Initial Issuance Shares and the Contingent Shares shall rank pari passu in all respects with the common
stock of the Purchaser issued as of the date hereof.

 

6.           Shareholder
Agreement.   With the exception of USMEN SpA, all holders of the Purchaser Shares are party to, and fully bound by
the provisions contained in, the Shareholder Agreement.

 

    	Schedule 3 to Stock Purchase Agreement
Page 17 of 17

    	 

    

  

Schedule 4

(Company Subsidiaries)

 

BioSynthema Global Operations, B.V., a
company organized under the laws of the Netherlands.

 

    	Schedule 4 to Stock Purchase Agreement
Page 1 of 1

    	 

    

  

Schedule 5

(Restricted Actions)

 

1.           Unless
the other Purchaser shall otherwise consent in writing, during the period from the date of this Agreement and continuing until
the earlier of the termination of the Agreement in accordance with Section 18 thereof or the Completion (the “Executory Period”),
except as expressly contemplated by this Agreement or as set forth in the Disclosure Letter with respect to the Company or Company
Subsidiaries, (i) the Company and the Company Subsidiaries shall conduct their business in all material respects in the ordinary
course of business consistent with past practice and (ii) the Company and Company Subsidiaries shall use commercially reasonable
efforts consistent with the foregoing to preserve intact, in all material respects, its business organization, to keep available
the services of its managers, directors, officers, employees and consultants, to maintain, in all material respects, existing relationships
with all persons with whom it does significant business, and to preserve the possession, control and condition of its assets consistent
with past practice.

 

2.           Without
limiting the generality of the foregoing Section (a), during the Executory Period, neither the Company nor any Company Subsidiary,
will, without the prior written consent of the Purchaser:

 

(i)          amend,
waive or otherwise change, in any respect, any of the Company Organizational Documents or Company Subsidiary Organizational Documents;

 

(ii)         authorize
for issuance, issue, grant, sell, pledge, dispose of or propose to issue, grant, sell, pledge or dispose of any of Common Stock,
or any options, warrants, commitments, subscriptions or rights of any kind to acquire or sell any of its Company Stock, or other
securities or equity interests, including any securities convertible into or exchangeable for any of its Common Stock or equity
interest of any class and any other equity-based awards, or engage in any hedging transaction with a third person with respect
to such Common Stock or other securities or equity interests;

 

(iii)        split,
combine, recapitalize or reclassify any of its equity interests or issue any other securities in respect thereof, declare, pay
or set aside any distribution or other dividend (whether in cash, equity or property or any combination thereof) in respect of
its equity interests, or directly or indirectly redeem, purchase or otherwise acquire or offer to acquire any of its capital equity
or other securities or equity interests, provided, however, the Company may declare, pay or set aside any distributions
in an amount equal to the Company’s accrual for Taxes as computed consistently with past practices and presented on the
Accounts;

 

(iv)        incur,
create, assume, prepay or otherwise become liable for any Indebtedness (directly, contingently or otherwise), make a loan or advance
to or investment in any third party, or guarantee or endorse any indebtedness, liability or obligation of any person;

 

    	Schedule 5 to Stock Purchase Agreement
Page 1 of 3

    	 

    

  

(v)         increase
the wages, salaries or compensation of any of its employees by more than five percent (5%), or increase bonuses for the foregoing
individuals in excess of five percent (5%), or make commitments to advance with respect to bonuses for fiscal year 2010 or 2011,
or materially increase other benefits of any of the foregoing individuals, or enter into, establish, materially amend or terminate
any Company Benefit Plan with, for or in respect of any current consultant, officer, manager director or employee, in each case
other than as required by applicable Law or pursuant to the terms of any Company Benefit Plan in effect on the date of this Agreement;

 

(vi)        make
or rescind any material election relating to Taxes, settle any claim, action, suit, litigation, proceeding, arbitration, investigation,
audit or controversy relating to Taxes, file any amended Tax Return or claim for refund, or make any change in its accounting or
Tax policies or procedures, in each case except as required by applicable Law or in compliance with US GAAP;

 

(vii)       transfer
or license to any person or otherwise extend, materially amend or modify, permit to lapse or fail to preserve any of the Company
Intellectual Property or Licensed Intellectual Property, or disclose to any person who has not entered into a confidentiality agreement
any trade secrets;

 

(viii)      terminate
or waive or assign any material right under any Company Material Contract or any Tenant Lease or enter into any contract;

 

(ix)         fail
to maintain its books, accounts and records in all material respects in the ordinary course of business consistent with past practice;

 

(x)          establish
any subsidiary or enter into any new line of business;

 

(xi)         fail
to use commercially reasonable efforts to keep in force insurance policies or replacement or revised policies providing insurance
coverage with respect to the assets, operations and activities of the Company and the Company Subsidiaries in an amount and scope
of coverage as are currently in effect;

 

(xii)        revalue
any of its material assets or make any change in accounting methods, principles or practices, except in compliance with US GAAP
and approved by the Company’s outside auditors;

 

(xiii)       waive,
release, assign, settle or compromise any claim, action or proceeding (including any suit, action, claim, proceeding or investigation
relating to this Agreement or the transactions contemplated hereby), other than waivers, releases, assignments, settlements or
compromises that involve only the payment of monetary damages (and not the imposition of equitable relief on, or the admission
of wrongdoing by, the Company or any of the Company Subsidiaries) or otherwise pay, discharge or satisfy any claims, liabilities
or obligations, unless such amount has been reserved in the Accounts as of the date hereof (and the Management Accounts as of the
Completion Date);

 

    	Schedule 5 to Stock Purchase Agreement
Page 2 of 3

    	 

    

  

(xiv)      close
or materially reduce the Company’s or any Company Subsidiary’s activities, or effect any layoff or other Company-initiated
personnel reduction or change;

 

(xv)       acquire,
including by merger, consolidation, acquisition of stock or assets, or any other form of business combination, any corporation,
partnership, limited liability company, other business organization or any division thereof, or any material amount of assets;

 

(xvi)      make
capital expenditures in excess of $20,000;

 

(xvii)     adopt
a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization;

 

(xviii)    voluntarily
incur any material liability or obligation (whether absolute, accrued, contingent or otherwise);

 

(xix)       sell,
lease, license, transfer, exchange or swap, mortgage or otherwise pledge or encumber (including securitizations), or otherwise
dispose of any material portion of its properties, assets or rights;

 

(xx)        enter
into any agreement, understanding or arrangement with respect to the voting or create any Encumbrance with respect to the Company
Shares or the capital equity of any Company Subsidiary;

 

(xxi)       take
any action that would reasonably be expected to delay or impair the obtaining of any consents or approvals of any Governmental
Entity to be obtained in connection with this Agreement;

 

(xxii)      enter
into, amend, waive or terminate (other than terminations in accordance with their terms) any Affiliate Transaction; or

 

(xxiii)     authorize
or agree to do any of the foregoing actions.

 

    	Schedule 5 to Stock Purchase Agreement
Page 3 of 3

    	 

    

  

Schedule 6

(Indemnification Obligations)

 

1.           Applicability;
Survival; Exclusive Remedy.    Byentering into this Agreement, each of the Shareholders expressly acknowledges
and agrees that it is becoming a party to, and shall have the obligations set forth, in this Schedule 6 (the “Indemnification
Obligations”). The representations and warranties of the Company, the Officers, Directors and the Shareholders made in or
pursuant to the Agreement will survive from the Completion Date until the date which is the earlier of (a) the fifth (5th)
anniversary of the Completion Date or (b) the date that the aggregate amount of all Damages claimed by the Purchaser or any Purchaser
Indemnified Party first reaches the Shareholder Indemnification Cap (as defined below) then in effect (the “Survival Period”).
Notwithstanding the foregoing, any representation or warranty the violation of which is made the basis of a claim for indemnification
pursuant to this Schedule 6 will survive until such claim is finally resolved if the Purchaser delivers a Purchaser Special Indemnification
Notice (as defined below) or a Purchaser General Indemnification Notice (as defined below) to the Shareholders prior to the expiration
of the Survival Period. Except as set forth in the immediately preceding sentence, no claim for indemnification under this Agreement
shall be brought after the expiration of the Survival Period.

 

2.           Indemnification
by the Shareholders.

 

2.1         Purchaser
Special Indemnification Claims.    In the event that the Purchaser delivers written notice of a Purchaser
Special Indemnification Claim (as defined below) setting forth the factual basis for such claim in reasonable detail (a “Claim
Notice”) to the Shareholder or Shareholders from whom indemnity is sought prior to the expiration of the Survival Period,
subject to the terms and conditions of this Schedule 6, each of the Shareholders shall severally indemnify and hold harmless the
Purchaser, its Affiliates and each of their respective successors and permitted assigns, and their respective officers, directors,
employees and agents (each, a “Purchaser Indemnified Party”) from and against any liabilities, claims (including claims
by third parties), demands, judgments, losses, costs, damages or expenses whatsoever (including reasonable attorneys’, consultants’
and other professional fees and disbursements of every kind, nature and description) (collectively, “Damages”), but
only to the extent of each such Shareholder’s pro rata portion of the Aggregate Consideration, that such Purchaser Indemnified
Party may sustain, suffer or incur and that result from, arise out of or relate to any of the following: (i) any breach of the
representations and warranties contained in Sections 2.2, 3.4, 3.7, 5.2 and 17.2 of Part A of Schedule 3 of this Agreement and/or
(ii) any fraud, intentional omission or willful misconduct committed by such Shareholder relating to this Agreement (each, a “Purchaser
Special Indemnification Claim”). Notwithstanding the foregoing, if the breach that is subject to the Purchaser Special Indemnification
Claim relates to a specific Shareholder or Purchaser Shares held by a specific Shareholder (such Shareholder, the “Breaching
Shareholder”), then Purchaser’s sole recourse for such Purchaser Special Indemnification Claim shall be against the
pro rata share of the Contingent Consideration paid or payable to the Breaching Shareholder.

 

    	Schedule 6 to Stock Purchase Agreement
Page 1 of 6

    	 

    

  

2.2         Purchaser
General Indemnification Claims.

 

(a)          In
the event that the Purchaser delivers a Claim Notice of a Purchaser General Indemnification Claim (as defined below) to the Shareholders
prior to the expiration of the Survival Period, subject to the terms and conditions of this Section 2.2, each of the Shareholders
shall severally indemnify and hold harmless each Purchaser Indemnified Party from and against any Damages that such Purchaser
Indemnified Party may sustain, suffer or incur and that result from, arise out of or relate to the following: (i) any breach by
the Company or any Company Subsidiary of any of their representations and warranties or covenants or agreements contained in this
Agreement, other than those that are included in the Purchaser Special Indemnification Claims and/or (ii) any fraud, intentional
omission or willful misconduct committed by the Company or any Company Subsidiary relating to this Agreement (each, a “Purchaser
General Indemnification Claim;” the Purchaser General Indemnification Claims and Purchaser Special Indemnification Claims
may be referred to collectively herein as “Purchaser Indemnification Claims”). The indemnification provided pursuant
to this Section 2.2 does not include any matter for which indemnification is provided pursuant to Section 2.1.

 

(b)          Unless
and until the aggregate value (the “Basket”) of all Purchaser General Indemnification Claims exceeds Twenty-Five Thousand
Euros (€ 25,000), the Purchaser shall not seek be entitled to offset any distributions of, or seek repayment of, any Contingent
Consideration due any payable or paid to the Shareholders in connection with their obligations pursuant to Section 2.2 of this
Schedule 6. At such time the Purchaser reasonably believes any Purchaser General Indemnification Claim will exceed the Basket,
it shall proceed in accordance with Section 2.2(a) and shall additionally enclose in its Claim Notice any previous payments made
as a result of any claim which did not exceed the Basket; provided that its failure to include such claims shall not prejudice
it in any manner. At such time the Purchaser Indemnification Claims exceed the Basket, Purchaser shall have the right to seek indemnification
in accordance with Section 2.2(c) for all Purchaser General Indemnification Claims, regardless of their value and whether such
Purchaser Indemnification Claims were held before or after the Basket was exceeded, but Subject to 2.2(d). All Purchaser Indemnification
Claims valued in a currency other than Euros shall be converted in accordance with the standard currency conversion practices of
the Purchaser, as recommended by Purchaser’s auditors. No Basket shall apply with respect to any Purchaser Special Indemnification
Claim.

 

(c)          All
Purchaser Indemnification Claims shall be satisfied (a) first by cancellation by the Purchaser of any payments of the Contingent
Cash Consideration that becomes payable by the Purchaser to each Shareholder (pro rata) after the date of the Purchaser General
Indemnification Notice, and (b) then by cancellation by the Purchaser of the obligations to issue any of the Contingent Shares
(valued at the Market Value) that become issuable by the Purchaser to the Shareholders after the date of the Claim Notice.

 

(d)          The
aggregate liability by the Shareholders for Damages pursuant to all Purchaser General Indemnification Claims shall not in any event
exceed the Shareholder

 

    	Schedule 6 to Stock Purchase Agreement
Page 2 of 6

    	 

    

 

Indemnification Cap
(and with respect to any Shareholder, shall not in any event exceed such Shareholder’s pro rata share of the Shareholder
Indemnification Cap).

 

(e)         “Shareholder
Indemnification Cap” shall mean:

 

(i)          for
Purchaser General Indemnification Claims made during the year beginning on the Completion Date and ending on the day before the
first (1st) anniversary of the Completion Date (the “First Year”), twenty-five percent (25%) of the Contingent
Consideration;

 

(ii)         for
Purchaser General Indemnification Claims made during the year beginning on the first (1st) anniversary of the Completion
Date and ending on the day before the second (2nd) anniversary of the Completion Date (the “Second Year”),
the amount that is (A) twenty percent (20%) of the Contingent Consideration less (B) the aggregate payment for Damages that were
the subject of Purchaser Indemnification Claims made during the First Year;

 

(iii)        for
Purchaser General Indemnification Claims made during the year beginning on the second (2nd) anniversary of the Completion
Date and ending on the day before the third (3rd) anniversary of the Completion Date (the “Third Year”),
the amount that is (A) fifteen percent (15%) of the Contingent Consideration less (B) the aggregate payment for Damages that were
the subject of Purchaser Indemnification Claims made during the First Year and the Second Year;

 

(iv)        for
Purchaser General Indemnification Claims made during the year beginning on the third (3rd) anniversary of the Completion
Date and ending on the day before the fourth (4th) anniversary of the Completion Date (the “Fourth Year”),
the amount that is (A) ten percent (10%) of the Contingent Consideration less (B) the aggregate payment for Damages that were the
subject of Purchaser Indemnification Claims made during the First Year, the Second Year and the Third Year; and

 

(v)         for
Purchaser General Indemnification Claims made during the year beginning on the fourth (4th) anniversary of the Completion
Date and ending on the fifth (5th) anniversary of the Completion Date (the “Fifth Year”), the amount that
is (Ai) five (5%) of the Contingent Consideration less (B) the aggregate payment for Damages that were the subject of Purchaser
Indemnification Claims made during the First Year, the Second Year, the Third Year and the Fourth Year.

 

3.           Third
Party Claims.    The indemnification obligations and liabilities under Schedule 6 with respect to Actions brought
against a Purchaser Indemnified Party by any person other than a party hereto (a “Third Party Claim”) shall be subject
to the following terms and conditions. The Purchaser, on behalf of the Purchaser Indemnified Party, will give written notice to
the Shareholders as soon as practical after receiving written notice

 

    	Schedule 6 to Stock Purchase Agreement
Page 3 of 6

    	 

    

 

of any Third Party Claim or becoming aware
of any condition or event that gives rise to such Third Party Claim, specifying the nature and the amount (the “Third Party
Claim Notice”) except as provided for in Section 1 of Schedule 6; provided, however, the Purchaser shall have
no obligation to provide a Third Party Claim Notice to any Shareholder named as a party in connection with such Third Party Claim.
Furthermore, the failure of the Purchaser to give timely notice shall not affect the Purchaser Indemnified Party’s rights
to indemnification hereunder except to the extent that the Majority Shareholders demonstrate the Shareholders were materially
prejudiced by such failure.

 

4.           Insurance
Coverage.    To the extent that any Damages that are subject to indemnification pursuant to this Schedule 6
are covered by insurance, the insured party shall use commercially reasonable efforts to obtain the maximum recovery under such
insurance. If the Purchaser Indemnified Party has received the payment required by this Agreement from the Shareholders in respect
of any Damages and later receives proceeds from insurance or other amounts in respect of such Damages, then it shall hold such
proceeds or other amounts in trust for the benefit of the Shareholders and shall pay to the Shareholders, as promptly as practicable
after receipt, a sum equal to the amount of such proceeds or other amount received, up to the aggregate amount of any payments
received from the Shareholders pursuant to this Agreement in respect of such Damages if such Damages were paid by the Shareholders
or up to the Indemnification Cap that was paid or payable; otherwise such insurance recovery shall be paid to the Indemnified Party
in an amount up to the Damages. Should such insurance recovery not meet or exceed the aggregate Damages, the remainder shall be
payable in accordance with this Schedule 6. Should such insurance recovery not meet or exceed the aggregate Damages, the Purchaser
may set-off such difference, pro rata, upon the next issuance of Contingent Consideration or recover such difference pursuant to
Section 5, below. Notwithstanding any other provisions of this Agreement, it is the intention of the parties that no insurer or
any other third person shall be (i) entitled to a benefit it would not be entitled to receive in the absence of the foregoing indemnification
provisions, or (ii) relieved of the responsibility to pay any claims for which it is obligated. To the extent that any Damages
that are subject to indemnification pursuant to this Schedule 6 are deductible for income tax purposes by a Purchaser Indemnified
Party, the amount of any Damages shall be reduced by the income tax savings to such Purchaser Indemnified Party as a result of
the payment of such Damages. To the extent that payments of any Damages that are subject to any Tax by a Purchaser Indemnified
Party, the amount of any Damages shall be increased by the income or other tax amount to be paid by such Purchaser Indemnified
Party as a result of the payment of such Damages.

 

5.           Recovery
of Contingent Consideration.   For the purposes of clarity, to the extent any such Contingent Consideration is paid
to the Shareholders, the Purchaser shall have the right to recover up to the Shareholder Indemnification Cap, pro rata from the
Shareholders, if the Damages pursuant to this Schedule 6 exceed any unearned Contingent Consideration. Each Shareholder hereby
acknowledges and agrees to return such Contingent Consideration, pro rata, not to exceed such Shareholder’s pro rata portion
of the Contingent Consideration, up to the amount of unpaid Damages as follows:

 

    	Schedule 6 to Stock Purchase Agreement
Page 4 of 6

    	 

    

  

within fifteen (15) days of notice of the final disposition
of any obligation indemnified pursuant to this Schedule 6 and such Shareholder’s respective pro rata portion thereof, each
Shareholder shall first return any Contingent Cash Consideration received by wire transfer of immediately available funds to the
account of the Purchaser and thereafter shall return any certificates representing the remainder in Contingent Shares which shall
be valued at the greater of Market Value or the price the Contingent Shares were valued at when issued to Shareholder.

 

[SIGNATURE PAGES TO FOLLOW]

 

    	Schedule 6 to Stock Purchase Agreement
Page 5 of 6

    	 

    

  

For and on behalf of:

Advanced Accelerator Applications
S.A.

 

	By:	/s/ Stefano Buono	 
	Name:	Stefano Buono	 
	Title:	President and Chief Executive Officer	 

 

For and on behalf of:

BioSynthema Inc.

 

	By:	/s/ Jack L. Erion	 
	Name:	Jack L. Erion	 
	Title:	Chief Executive Officer	 

 

For and on behalf of the undersigned
Shareholder:

 

	By:	 	 
	Name:	 	 
	Title:	 	 

  

    	Schedule 6 to Stock Purchase Agreement
 

    	 

    

  

Schedule 7

Accounts as of December 31, 2009

 

    	Schedule 7 to Stock Purchase Agreement
Page 1 of 1

    	 

    

  

BioSynthema Inc.

Balance Sheet

As of December 31, 2009

 

	 	 	Total	 
	ASSETS	 	 	 	 
	Current Assets	 	 	 	 
	Bank Accounts	 	 	 	 
	0100 US Bank 2605	 	 	92,863.00	 
	0210 1ST IBI	 	 	10,688.29	 
	0220 E*TRADE	 	 	24,771.38	
	230 Savings EURO account	 	 	106,071.27	 
	Total Bank Accounts	 	$	234,393.94	 
	Accounts Receivable	 	 	 	 
	1200 Accounts Receivable	 	 	0.00	 
	Total Accounts Receivable	 	$	0.00	 
	Other Current Assets	 	 	 	 
	1120 Inventory Asset	 	 	0.00	 
	1499 Undeposited Funds	 	 	20.00	 
	1510 Employee Advances	 	 	40.13	 
	Custom Chemicals	 	 	54,500.00	 
	Custom Peptide Inventory	 	 	121,491.00	 
	Investment - Amersterdam	 	 	26,856.00	 
	Investments - Savings Accounts	 	 	0.00	 
	Laboratory Supplies	 	 	23,857.00	 
	Prepaid Professional Fees	 	 	75,990.54	 
	Vendor Receivables	 	 	36.50	 
	Total Other Current Assets	 	$	302,751.17	 
	Total Current Assets	 	$	537,145.11	 
	Fixed Assets	 	 	 	 
	Computers & Peripherals	 	 	12,716.63	 
	Accum. Dep - PC's and Periph.	 	 	11,258.57	 
	Total Computers & Peripherals	 	$	1,458.06	 
	Laboratory Equipment	 	 	138,390.00	 
	Depreciation	 	 	440,569.58	 
	Original Cost	 	 	303,319.99	 
	Total Laboratory Equipment	 	$	1,140.41	 
	Miscellaneous Lab Equipment	 	 	25,000.00	 
	Office Furniture	 	 	1,402.98	 
	Accumulated Depreciation	 	 	1,402.98	 
	Total Office Furniture	 	$	0.00	 
	Total Fixed Assets	 	$	27,598.47	 
	Other Assets	 	 	 	 
	Intangible Asset - Patents	 	 	248,662.48	 
	Case 1020	 	 	0.00	 
	Case 1405	 	 	16,692.43	 
	Case 1406	 	 	61,104.65	 
	Case 1410	 	 	62,855.75	 
	Case 1488	 	 	6,929.27	 
	Case 1514	 	 	0.00	 
	Case 1601	 	 	19,386.30	 
	Case 1602	 	 	6,627.68	 
	Case 1604	 	 	2,130.11	 
	Case 1605	 	 	5,543.91	 
	Case 1606	 	 	26,995.65	 
	Case 728	 	 	0.00	 
	Case 755	 	 	0.00	 
	Case 836	 	 	779.90	 
	Case 947	 	 	0.00	 
	Total Intangible Asset - Patents	 	$	457,708.13	 
	Other Long-Term Assets	 	 	78,784.56	 
	Security Deposits	 	 	5,971.08	 
	Total Other Assets	 	$	542,463.77	 
	TOTAL ASSETS	 	$	1,107,207.35	 

 

    	 

    	 

    

  

	LIABILITIES AND EQUITY	 	 	 
	Liabilities	 	 	 
	Current Liabilities	 	 	 
	Accounts Payable	 	 	 
	2000 Accounts Payable	 	 	0.00	 
	Total Accounts Payable	 	$	0.00	 
	Credit Cards	 	 	 	 
	AMERICAN EXPRESS	 	 	 	 
	AEC6-91004 - F Sorenson	 	 	0.00	 
	Total AMERICAN EXPRESS	 	$	0.00	 
	Total Credit Cards	 	$	0.00	 
	Other Current Liabilities	 	 	 	 
	2200 Sales Tax Payable	 	 	0.00	 
	2300 Directors Trust Accounts - Liabilities	 	 	 	 
	2310 H van Rossem Trust Accounts - Liabilities	 	 	7,200.00	 
	Total 2300 Directors Trust Accounts - Liabilities	 	$	7,200.00	 
	Accrued Liabilities	 	 	985.61	 
	Employee Payables	 	 	0.00	 
	Employee reimbursement	 	 	37.00	 
	Total Other Current Liabilities	 	$	6,251.39	 
	Total Current Liabilities	 	$	6,251.39	 
	Long Term Liabilities	 	 	 	 
	Stichting BWE	 	 	671,925.00	 
	Total Long Term Liabilities	 	$	671,925.00	 
	Total Liabilities	 	$	678,176.39	 
	Equity	 	 	 	 
	1110 Retained Earnings	 	 	88,207.80	 
	1520 Capital Stock	 	 	100.00	 
	3000 Opening Bal Equity	 	 	0.00	 
	Capital In Excess of Par	 	 	673,983.00	 
	Net Income	 	 	156,844.24	 
	Total Equity	 	$	429,030.96	 
	TOTAL LIABILITIES AND EQUITY	 	$	1,107,207.35	 

 

Friday, May 07, 2010 03:29:16 PM GMT-5 -
Accrual Basis

 

    	 

    	 

    

  

BioSynthema Inc.

Statement of Cash Flows

January - December 2009

 

	 	 	Total	 
	OPERATING ACTIVITIES	 	 	 	 
	Net Income	 	 	156,844.24	 
	Adjustments to reconcile Net Income to Net Cash provided by operations:	 	 	 	 
	1200 Accounts Receivable	 	 	2,553.40	 
	Prepaid Professional Fees	 	 	75,990.54	 
	Vendor Receivables	 	 	25.08	 
	2000 Accounts Payable	 	 	6,883.41	 
	2200 Sates Tax Payable	 	 	0.00	 
	Net cash provided by operating activities	 	$	237,139.71	 
	INVESTING ACTIVITIES	 	 	 	 
	Computers & Peripherals: Accum. Dep - PC's and Periph.	 	 	1,031.28	 
	Laboratory Equipment: Depreciation	 	 	1,710.00	 
	Laboratory Equipment: Original Cost	 	 	2,849.99	 
	Office Furniture: Accumulated Depreciation	 	 	43.72	 
	Intangible Asset - Patents: Case 1405	 	 	1,053.46	 
	Intangible Asset - Patents: Case 1406	 	 	9,310.20	 
	Intangible Asset - Patents: Case 1410	 	 	7,657.51	 
	Intangible Asset - Patents: Case 1602	 	 	2,453.57	 
	Intangible Asset - Patents: Case 1605	 	 	2,000.00	 
	Intangible Asset - Patents: Case 1606	 	 	13,340.45	 
	Security Deposits	 	 	1,185.10	 
	Net cash provided by investing activities	 	$	37,056.28	 
	FINANCING ACTIVITIES	 	 	 	 
	3000 Opening Bal Equity	 	 	21.72	 
	1110 Retained Earnings	 	 	21.67	 
	Net cash provided by financing activities	 	$	0.05	 
	Net cash increase for period	 	$	274,204.94	 
	Cash at beginning of period	 	 	508,578.88	 
	Cash at end of period	 	$	234,373.94	 

 

Friday, May 07, 2010 03:34:05 PM GMT-5

 

    	 

    	 

    

  

BioSynthema Inc.

Profit & Loss

January - December 2009

 

	 	 	Total	 
	Income	 	 	 	 
	4070 Services	 	 	116,027.99	 
	Peptide Sales	 	 	139,373.30	 
	Shipping Income	 	 	31.30	 
	Total Income	 	$	255,432.59	 
	Gross Profit	 	$	255,432.59	 
	Expenses	 	 	 	 
	6120 Bank Service Charges	 	 	66.50	 
	6150 Depreciation Expense	 	 	2,785.00	 
	6160 Dues and Subscriptions	 	 	261.30	 
	6180 Insurance	 	 	 	 
	Medical	 	 	5,655.18	 
	Total 6180 Insurance	 	$	5,655.18	 
	6200 Interest Expense	 	 	 	 
	6210 Finance Charge	 	 	3.95	 
	Total 6200 Interest Expense	 	$	3.95	 
	6230 Licenses and Permits	 	 	202.00	 
	6240 Miscellaneous	 	 	68.59	 
	6250 Postage and Delivery	 	 	1,768.66	 
	6270 Professional Fees	 	 	13,402.83	 
	6275 Payroll Services	 	 	1,850.85	 
	6280 Legal Fees	 	 	0.00	 
	General Legal Services	 	 	0.00	 
	Legal Fees - Patent	 	 	567.06	 
	Total 6280 Legal Fees	 	$	567.06	 
	6650 Accounting	 	 	2,429.39	 
	Total 6270 Professional Fees	 	$	18,250.13	 
	6290 Rent	 	 	71,809.96	 
	6340 Telephone	 	 	1,555.96	 
	6350 Travel & Ent	 	 	 	 
	6360 Entertainment	 	 	55.03	 
	6370 Meals	 	 	751.11	 
	6380 Travel	 	 	1,176.74	 
	Lodging	 	 	658.80	 
	Miscellaneous	 	 	158.93	 
	Total 6350 Travel & Ent	 	$	2,800.61	 
	6560 Payroll Expenses	 	 	 	 
	FICA / Med Tax	 	 	 	 
	FICA / Med Tax - Employees	 	 	9,835.49	 
	Total FICA / Med Tax	 	$	9,835.49	 
	FUTA / SUI	 	 	 	 
	FUTA / SUI - Employees	 	 	650.36	 
	Total FUTA / SUI	 	$	650.36	 
	Wages	 	 	 	 
	Wages - Employees	 	 	67,230.90	 
	Wages - Officers	 	 	58,971.85	 
	Total Wages	 	$	126,202.75	 
	Total 6560 Payroll Expenses	 	$	136,588.60	 

 

    	 

    	 

    

  

	6820 Taxes	 	 	62.00	 
	6830 Federal	 	 	0.00	 
	6850 Property	 	 	1,189.56	 
	6860 State	 	 	424.00	 
	Payroll Expense	 	 	552.69	 
	Total 6820 Taxes	 	$	2,104.25	 
	Consulting	 	 	147,467.59	 
	Education & Training	 	 	599.31	 
	Equipment - Misc	 	 	167.29	 
	Equipment Maintenance	 	 	1,934.70	 
	Maintenance - Lab Equipment	 	 	310.00	 
	Parking	 	 	87.40	 
	Peptide Synthesis	 	 	1,800.00	 
	Software	 	 	49.95	 
	Supplies	 	 	 	 
	Lab	 	 	13,635.20	 
	Office	 	 	1,190.90	 
	Total Supplies	 	$	14,826.10	 
	Waste Expense	 	 	1,263.42	 
	Total Expenses	 	$	412,526.45	 
	Net Operating Income	 	$	157,093.86	 
	Other Income	 	 	 	 
	7010 Interest Income	 	 	249.62	 
	Total Other Income	 	$	249.62	 
	Net Other Income	 	$	249.62	 
	Net Income	 	$	156,844.24	 

 

Friday, May 07, 2010 03:21:10 PM GMT-5 - Accrual BasisExhibit 10.4

 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES
ACT OF 1933, AS AMENDED.

 

[*] INDICATES OMITTED MATERIAL THAT IS THE
SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY
WITH THE COMMISSION.

 

KNOW HOW and TRADEMARK LICENCE AGREEMENT

 

BETWEEN:

 

IASON GmbH a company organised and existing
under the laws of Austria, whose registered office is at Feldkirchner Straße 4, A-8054 Graz-Seiersberg represented
by Mr Mag. Christoph Artner in his capacity of CEO, (hereinafter “LICENSOR”)

 

- on the one hand -

 

AND :

 

Advanced Accelerator Applications S.A.,
a company organised and existing under the laws of France, whose registered office is at 20 rue Diesel 01630 Saint Genis Pouilly
(France), represented by Stefano Buono, in his capacity of President and General Director (hereinafter the “LICENSEE”)

- on the other hand -

 

WHEREAS:

 

		A.	LICENSOR has developed the formulation of the pharmaceutical Product(s) described in Schedule A
hereto (« the Product(s) ») and owns a body of scientific, technical and marketing information and know-how
relating to the Product(s).

 

		B.	LICENSOR is the registered owner of the trademark(s) shown in Schedule B hereto which is/are registered
in different countries as given in Schedule B.

 

		C.	LICENSOR has obtained from the competent authorities the Marketing Authorisation according to pharmaceutical
legal rules to sell and market the Product in the countries given in Schedule C.

 

		D.	LICENSOR as the Marketing Authorisation Holder (MAH), is responsible for all aspects of the Product,
including quality and compliance with the conditions of marketing authorisation.

 

		E.	LICENSOR wishes to grant LICENSEE the right to manufacture the Product(s) by using the LICENSOR’s
know-how and the right to sell and to promote the sales of the Product(s) in France, Spain, Belgium, Luxembourg, The Netherlands,
French Cantons of Switzerland, and the following regions of Italy: Valle d ́Aosta, Piemonte, Liguria, WesternPart of the regions
of Lombardia and Emilia Romagna, including the city of Parma, according to the map attached
hereto as Schedule D (the “Territory”). The city of 

 

    	 

    	 

    

 

Parma is belonging to LICENSEE ́s
region. For Southern Italy, LICENSOR intends to grant LICENSEE this right under a special agreement to be defined within the year
2009.

 

		F.	Except for the equipments mentioned under letter G below, LICENSEE has all necessary industrial
equipment and commercial resources for manufacturing and selling the Product(s) in the Territory and is willing to do so in its
own name and on its own account.

 

		G.	LICENSOR will supply and install all necessary technical equipments (Technical Equipment as specified
in Schedule H) as better specified in this agreement and upon the terms and conditions set forth under paragraph 3.1. and Schedule
E of this contract.

 

IT WAS THEREFORE AGREED AS FOLLOWS:

 

		1.	DEFINITIONS

 

In this Agreement:

 

« Affiliate »
means any company, firm, partnership or other legal entity which (a) directly or indirectly owns or controls, or (b) is owned or
controlled by, or (c) is under common control or ownership with, either party.

 

« Authorities »
means the competent authorities which authorise the importation and/or sale of the Product(s) in the Territory.

 

« Effective Date »
means the date of first production of LICENSOR ́s Product on LICENSEE ́s site after having accomplished Variation Type
II for LICENSEE ́s site for first Product under this agreement.

 

« Execution Date »
means the date of signature of this Agreement by both parties as set out at the top of page 1.

 

« Force Majeure »
means any circumstances beyond the reasonable control of either party including, without limitation, any decision of the Authorities
or other governemental bodies, strike, lock-out or other form of industrial action.

 

«Improvement» means any
development or enhancement of the Know-How which would make the Product(s) cheaper, more effective, more useful or more valuable,
or which would in any other way render the Product(s) preferable in commerce when compared to other competitive Product(s).

 

«Inventing Party» has the
meaning set out in clause 6.1(a).

 

«Know-How» means any methods,
techniques, processes, discoveries or inventions, whether patentable or not, specifications, recipes, formulae, designs, plans,
drawings, data or other technical, scientific or marketing information.

 

«LICENSOR’s Know-How »
means any Know-How relating to the Product(s), their manufacture and their marketing, which has been developed or acquired by the
LICENSOR

 

    	2

    	 

    

 

on or before the date of this Agreement, or
which shall be developed or acquired by the LICENSOR after such date, including but not limited to :

		-	the methods of manufacturing,

		-	the technical specifications and formula,

		-	the methods of quality control,

		-	the design and get-up of the packaging and labelling including the LICENSOR’s logo,

		-	the methods of marketing, advertising and sales promotion,

		-	all scientific and medical data, including all data contained in the Registration Dossier.

 

«LICENSOR’s Corporate Design
Guidelines» means the LICENSOR’s guidelines relating to the use of LICENSOR’s corporate Logo and Trademark
on packagings and advertising materials.

 

“Module 3”is the section
of any Marketing Authorisation concerning the industrial process for production of the Product to which the Marketing Authorisation
refers.

 

« Product(s)» means
the pharmaceutical Product(s) in its/their finished form as described in Schedule A.

 

« Production Sites»
are the sites within the Territory, where the LICENSEE envisages to manufacture the Products as listed in Schedule A, and any further
production site that the LICENSEE may add to the attached list from time to time (“New Production Sites”), by
written notice to the LICENSOR.

 

« Product Licence(s) »
means the authorisation(s) issued by the Authorities to manufacture and/or import and/or market the Product(s) in the Territory,
including any Variation Type II filed by the LICENSOR with reference to any of the LICENSEE’s Production Sites.

 

« Territory »
has the meaning ascribed to it in letter E of the premises..

 

« Trademark(s) »
means the LICENSOR’s registered and not registered trademark(s) as set out in Schedule B hereto and, except where the context
otherwise requires, any copyright or other intellectual property rights of the LICENSOR in respect of the get-up of the Product(s)
and the design of the packaging and labelling of the Product(s).

 

“Variation Type II” means
the authorisation by the Authorities of the “variation” of the Marketing Authorisation, which is necessary in order
to include a new production site in the Marketing Authorisation and, thus, produce and market the Product(s) from such production
site.

 

		2.	LICENCE AND ROYALTIES

 

		2.1.	Under the terms and conditions hereinafter set out, the LICENSOR hereby grants LICENSEE and LICENSEE
hereby accepts the grant of :

 

		(a)	an exclusive licence to use the LICENSOR’s Know-How for the purpose of manufacturing and
selling the Product(s) in the Territory and

 

		(b)	an exclusive licence to use the Trademark(s) in relation thereto.

 

    	3

    	 

    

 

		2.2.	As a result of the rights granted under clause 2.1, the LICENSOR shall not, during the term of
this Agreement, grant any third party the right to use the LICENSOR’s Know How and/or the Trademark(s), neither for manufacturing
the Product(s) for sale in the Territory nor for selling or promoting the sales of the Product(s) in the Territory.

 

		2.3.	As a result of the rights granted under clause 2.1, LICENSEE shall not, during the term of this
Agreement, except with the LICENSOR’s prior written consent:

 

		(a)	assign, transfer or sub-license any of its rights or sub-contract or otherwise delegate any of
its obligations under this Agreement to any third party ;

 

		(b)	manufacture the Product for sale outside the Territory or sell the Product(s) outside the Territory.

 

		2.4.	As remuneration of the rights granted under clause 2.1 above, in full consideration of all benefits afforded under this Agreement,
LICENSEE shall pay the LICENSOR a royalty according to Schedule E.

		2.5.	Royalty payments shall be made every 3 months. LICENSEE shall provide the LICENSOR by the 30th
day after each three-month period with a written report showing all necessary data, mainly production amounts (no. of batches performed)
of the Product(s) during the immediately preceding three-month period and calculation of the due royalties according to paragraph
2.4 above. LICENSOR will then issue an invoice to LICENSEE for the amount of said royalties and LICENSEE will then pay the invoice
within 30 days of receipt. Payment shall be made to LICENSOR to the following bank account, or any other bank account subsequently
and timely communicated from LICENSOR to LICENSEE in writing.

 

Steiermärkische Bank und Sparkassen
AG

BIC: [•]

IBAN : [•]

 

		2.6.	LICENSEE shall give LICENSOR access to the LICENSEE’s production records and pharmaceutical
documentation concerning the Products under this agreement, in order to verify the declared no. of batches produced.

 

		2.7.	In case of a disagreement between the parties as to the no. of batches produced, the LICENSOR will
also have access to all sale records of the Product(s), in order to be able to verify correlation between net sales figures of
Product(s) and no of batches declared.

 

		2.8.	The rights under 2.6. and 2.7. can be exercised on a quarterly basis.

 

		3.	PRODUCT LICENCE(S)

 

		3.1	As soon as possible after the Execution Date, the LICENSOR shall, at its own cost provide LICENSEE
with:

 

    	4

    	 

    

 

(a) one copy of the Marketing Authorisation
for each Product, together with all necessary pharmaceutical and technical information and documentation, which is necessary for
the LICENSEE to start the production under this contract. The Qualified persons of both parties have agreed upon such documentation
as described in Schedule F.

 

(b) any and all LICENSOR’s
Know-How in order to enable LICENSEE to prepare and finalise in due time and under the LICENSOR ́s guidance all documents,
forms, reports, records, studies, protocols, product information and any other information required or useful to file and or obtain
LICENSOR ́s Variation Type II for each of the LICENSEE’S Production Site in relation to each Product and any other Product
Licence(s) possibly required in order for the LICENSEE to manufacture, import and/or market the Products in the Territory.

 

(c) installation of the necessary
technical equipment for production of the Products under this agreement, as specifically identified in Schedule H to this agreement
(the “Technical Equipment”). The Technical equipment shall comply with the specifications detailed in Schedule
H and shall be supplied and installed at each Production Site according to the time schedule shown in Schedule H. The LICENSOR
shall also provide the LICENSEE with the after sale service in relation to the Technical Equipment supplied to LICENSEE, as provided
in Schedule H. Supply, installation and after sale service of the Technical Equipment shall be entirely remunerated by the LICENSEE
with the “basis fee” provided in Schedule E, per each Production Site. LICENSEE has to provide the necessary
technical installation to produce the needed nuclide in the target (see schedule H). If additional equipment has to be ordered
from a third party, LICENSOR will do that on the account of LICENSEE after prior consensus of the latter about the items and services
to be ordered. LICENSEE will in no case order equipment from a third party to avoid disagreement between the parties as to the
responsibility for the quality of the technical equipment installed by LICENSOR.

 

		3.2	LICENSOR shall in its name and at its own cost:

 

(a) Perform all necessary validation
works on the site of the LICENSEE, which are basis for production of the necessary site specific documents as described in 3.1.a.
under responsibility of the LICENSOR on the LICENSEE ́s production site.

 

(b) file an application for obtaining
the Variation Type II for each Product and for each LICENSEE’S Production Site and any other Product Licence(s) with the
Authorities as soon as practically possible after signing this Agreement or, in case of New Production Sites, as soon as practically
possible after the reception of the GMP authorisation delivered by the competent Authorities;

 

(c) take any other action that may
be required by the Authorities for granting the Variation Type II or other Product Licences possibly required in order for
the LICENSEE to manufacture, import and/or market the Products in the Territory.

 

    	5

    	 

    

 

		3.3	As soon as the Variation Type II or any other Product Licence(s) is/are issued by the Authorities,
LICENSOR shall inform LICENSEE in writing and shall provide the LICENCEE with one copy thereof.

 

		4.	CONFIDENTIALITY

 

		4.1.	During the term of this Agreement and after its termination, LICENSEE shall not, except as provided
by sub-clause 4.2, disclose to any third party or use for any purpose other than contemplated by this Agreement, any part of the
LICENSOR’s Know-How or any other information which has been or will be disclosed by the LICENSOR to LICENSEE under or pursuant
to this Agreement, which is marked in writing as confidential (“LICENSOR’s Confidential Information”).

 

		4.2.	Any LICENSOR’s Confidential Information may be :

 

		(a)	disclosed by LICENSEE to (i) the Authorities or (ii) any other person, to the extent required by
applicable laws; or

 

		(b)	disclosed by LICENSEE to any of its own employees or to employees of its own Affiliates to the
extent necessary for the manufacture and sale of the Product(s), subject to LICENSEE imposing upon such employees a written undertaking
to comply with obligations identical to those set out in sub-clause 4.1.

 

		4.3.	The obligation of secrecy and non-use shall not apply to such LICENSOR’s Confidential Information
which the LICENSEE has provided to the LICENSOR in writing that:

 

		(a)	is or becomes in the public domain without violation of
this Agreement, or

		 	 

		(b)	has been legitimally received from a third party, without
violation of this Agreement.

 

		4.4.	Upon termination of this Agreement the LICENSEE shall be
obliged to promptly return to the LICENSOR, without being requested to do so, all samples, documents, electronic records, data
carriers and other storage media which the LICENSOR hands over to the LICENSEE within the scope of the cooperation under this
Agreement or makes available to the LICENSEE in any other way. With respect to this obligation, the LICENSEE hereby waives any
right of retention irrespective of ots legal basis. Furthermore, the LICENSEE undertakes not to make any copies, electronic storage
or any other records of the documents handed over and to promptly and completely destroy and/or delete any that have necessarily
been made, and to confirm this in writing at the LICENSOR’s request.

 

		5.	DISCLOSURE OF THE LICENSOR’s KNOW-HOW and TECHNICAL ASSISTANCE

 

		5.1.	As soon as practicable after the Execution Date, the LICENSOR shall disclose the LICENSOR’s
Know-How to LICENSEE in sufficient detail to enable LICENSEE to manufacture the Product(s) on an industrial basis. Thereafter,
the LICENSOR shall,

 

    	6

    	 

    

 

during the term of this Agreement,
disclose to LICENSEE any modification to the LICENSOR’s Know-How.

 

		5.2.	The LICENSOR represents and warrants to the LICENSEE that:

 

		-	the LICENSOR is the owner of the LICENSOR’s Know-How and of the Trademark(s) and has full
right and authority to give and grant all rights and licences for the use of the LICENSOR’s Know-How and Trademark(s) in
the Territory in connection with the manufacture and sale of the Product(s);

 

		-	the use by the LICENSEE of the LICENSOR’s Know-How and of the Trademark(s) in the Territory
does not infringe any third party’s right;

 

		-	the performance by LICENSOR of its obligations under this Agreement does not contravene any provision
of law, regulation, judgment, order, certificate of incorporation, by-laws, agreement or other instruments to which the LICENSOR
or any of its property is subject.

 

		5.3.	Nothing in this Agreement shall be construed as imposing any obligation upon the LICENSOR to engage
in any scientific or technical study relating to the Product(s).

 

		5.4.	During a period of 2 months from the Execution Date:

 

		(a)	LICENSEE shall be entitled, at its own cost, to send to the LICENSOR’s premises where the
Product(s) is/are manufactured suitably qualified employees of LICENSEE for training in the manufacture of the Product(s) and use
of the LICENSOR’s Know-How;

 

		(b)	the LICENSOR shall, if so requested by LICENSEE, make available to LICENSEE, at LICENSEE’s
cost and for a period not exceeding 5 man days in any quarter, the services of suitably qualified employees of the LICENSOR to
provide technical assistance at LICENSEE’s premises in relation to the manufacture of the Product(s) and the use of the LICENSOR’s
Know-How in relation thereto;

 

		(c)	the number of employees of each party who shall visit the other party’s premises pursuant
to paragraphs (a) and (b) above and the time and duration of such visits shall be agreed in advance by mutual consent of both parties ;

 

		(d)	Any employees of either party who shall visit the other party’s premises pursuant to paragraphs
(a) and (b) above shall remain employed by the party which sends them and this party shall :

 

		(i)	ensure that each such employee complies with all security, health and safety and other regulations
in force at the premises visited and

 

		(ii)	Indemnify the other party against any damage to this other party’s property or any personal
injury to any individual which is caused by the negligent act or omission of any such employee at the other party’s premises.

 

    	7

    	 

    

 

		6.	IMPROVEMENTS

 

		6.1.	If any time during the term of this Agreement, either party makes, devises or otherwise acquires
any Improvement, it shall, as soon as reasonably practicable, disclose the Improvement to the other party in the same conditions
as those set out in sub-clause 5.1 and 5.2 above, provided however that such obligation shall not apply to the extent that or for
so long as :

 

		(a)	the party which makes or acquires the Improvement (« the Inventing Party »)
is precluded from doing so by law or any obligation owed to any third party, or

 

		(b)	the disclosure of the Improvement would prejudice the ability of the Inventing Party to obtain
a patent or any other intellectual property protection in respect of the Improvement.

 

		6.2.	Whenever the LICENSOR is the Inventing Party, any Improvement
which is disclosed by the LICENSOR to LICENSEE pursuant to sub-clause 6.1 shall be deemed to be included in the definition
of the LICENSOR’s Know-How and LICENSEE shall have the same rights upon such Improvement as those granted by the LICENSOR
upon the LICENSOR’s Know-How under this Agreement.

 

		6.3.	Whenever LICENSEE is the Inventing Party, any Improvement which is disclosed by LICENSEE to the
LICENSOR pursuant to sub-clause 6.1 (« LICENSEE’s Improvement ») shall belong to LICENSEE and shall
be subject to the following conditions :

 

		(a)	LICENSEE shall be entitled, without the LICENSOR’s prior consent, to:

 

		-	apply at its own cost for any patent upon any LICENSEE’s
Improvement;

		-	use any LICENSEE’s Improvement for manufacturing or selling the Product(s) or for any other
purpose, including granting any license thereupon to any third party; provided that such LICENSEE’s
Improvement is separable from, and not dependent upon, the LICENSOR’s Know-How.

 

		(b)	LICENSEE shall be entitled, without the LICENSOR’s prior consent, to use any LICENSEE’s
Improvement for manufacturing or selling the Product(s) or for any other purpose, including granting any license thereupon to any
third party provided however that (i) such LICENSEE’s Improvement is separable from, and not dependent upon, the LICENSOR’s
Know-How and (ii) such license does not involve any disclosure of THE LICENSOR’s Know-How ;

 

		(c)	In any case the LICENSOR shall be entitled to manufacture, use, sell or otherwise deal in any Product(s)
manufactured through the use of any LICENSEE’s Improvement by way of a non-exclusive, worldwide, perpetual and royalty-free
licence;

 

		7.	MANUFACTURE AND PACKAGING of the PRODUCT(S) 

 

During the term of this Agreement, LICENSEE
shall:

 

    	8

    	 

    

 

		(a)	manufacture and pack the Product(s) in conformity with :

 

		(i)	the LICENSOR’s Know-How and all other written instructions from THE LICENSOR, in conformity
with the Registration Dossier and/or the Product Licence, and

 

		(ii)	all applicable legal and regulatory requirements ;

 

		(b)	ensure that all packagings and labellings for the Product(s) comply with all applicable legal and
regulatory requirements in the Territory and with the LICENSOR’s Corporate Design Guidelines

 

		(c)	permit the LICENSOR’s authorised representatives, at any time during normal working hours
and on reasonable advance notice (not shorter than two weeks) to enter the premises of LICENSEE where the Product(s) is/are manufactured,
packed or stored, in order to check exclusively their conformity with the above provisions, provided a date for the visit is agreed
at least 2 weeks in advance;

 

		(d)	permit the LICENSOR ́s authorised persons to perform regular audits in the following fields:

compliance with GMP-rules

production files of Products under
this contract

provided that a date for the audit
is agreed at least 2 weeks in advance;

 

		(e)	permit the LICENSOR ́s authorised persons to perform Audits on emergency occasion in the following fields, with a prior
notice of at least 3 working days:

fields listed under (d)

radiation protection

packing and shipping in compliance with ADR and IATA.

  

		8.	MARKETING and SALE of the PRODUCT(S)

 

		8.1.	During the term of this Agreement, LICENSEE shall:

 

		(a)	Use its best commercial endeavours to promote the sales of the Product(s) throughout the Territory;

 

		(b)	sell and market the Product(s) in the Territory only in packagings and labellings conforming with
the provisions of sub-clause 7 (b) ;

 

		(c)	refrain from (i) using the Trademark(s) for any other purpose than as permitted under this Agreement;

 

		(d)	notify the LICENSOR in writing of any serious adverse reaction to the Product(s).

For the purpose of this paragraph,
a serious adverse reaction shall mean any medical occurrence following the use of the Product(s) which (i) results in patient’s
death or (ii) requires the patient to be hospitalised or to prolong hospitalisation or (iii) results in a

 

    	9

    	 

    

 

persistent or significant disability
or incapacity or (iv) is life threatening or (v) involves a malignancy or congenital anomaly;

 

Install a Documentation Management
for all type of customer claims, starting from low-level complaints upon delivery delays, logistic failures, etc. on a quarterly
base.

 

		(e)	inform the LICENSOR as soon as it becomes aware of (i) the introduction in the Territory of any
Competitive Product or (ii) any infringement to the Trademark(s) or (iii) any decision from the Authorities to suspend or discontinue
the sale of the Product (s) in the Territory and/or to recall from the Customers the Product(s) already delivered to them;

 

		8.2.	Any production and distribution of Products under this contract as free samples for the customers
and/or members of the medical profession in the Territory can be done by LICENSEE on his own decision and costs. Nevertheless LICENSEE
shall pay to LICENSOR the royalty according to Schedule E without any reduction.

 

		9.	PROTECTION OF THE LICENSOR’s KNOW-HOW and OF THE TRADEMARK

 

		9.1.	LICENSOR shall, at its own cost :

 

		(a)	obtain, maintain and renew all existing and future registrations of the Trademark(s) in the Territory,

 

		(b)	take all actions which the LICENSOR shall deem advisable to protect and defend the Trademark(s)
against illicit copy, imitation or infringement by any third party in the Territory.

 

		9.2.	LICENSEE shall inform the LICENSOR of:

 

		(a)	any claim threatened or made against LICENSEE by any person alleging that the use of the LICENSOR’s
Know-How or the Trademark(s) infringes any intellectual property right or other rights of third parties,

 

		(b)	any illicit copy, imitation or infringement by any person in the Territory of the Trademark(s)
or the get-up of the Product(s) or the packaging or labelling thereof of which LICENSEE officially becomes aware;

 

provided however that LICENSEE shall
take no action in relation thereto except as LICENSOR may reasonably require pursuant to sub-clauses 9.4.

 

		9.3	LICENSEE shall take all such steps as LICENSOR may reasonably require to assist the LICENSOR in:

 

		(a)	maintaining the validity or enforceability of LICENSOR’s rights on LICENSOR’s Know-How
or the Trademark(s) in the Territory or

 

    	10

    	 

    

 

		(b)	taking actions for illicit copy, imitation or infringement of the Trademark(s) in the Territory.

 

		9.4	LICENSEE shall be obliged, to provide the contractual Product’s manufactured by the LICENSEE
or by order of the LICENSEE with serial numbers and mark them as given in the SPC (Summary of Product Characteristics) after having
achieved the Variation Type II under French authorithies guidance. A proposal for the labelling to be proposed at Variation Type
II application is attached as Schedule G.

 

    	11

    	 

    

 

		10.	TERM and TERMINATION

 

		10.1	This Agreement shall enter
                                         into force on the Execution Date and shall continue for an initial period of 5 years
                                         from the Effective Date and thereafter for successive periods of 1 year each,
                                         until and unless terminated by either party pursuant to any of the following clauses.

 

		10.2	Either party may terminate
                                         this Agreement by the end of the initial period or of any subsequent period, subject
                                         to giving the other party notice to that effect not less than 9 months in advance. In
                                         case of termination of this contract by the LICENSOR prior to the initial period of 5
                                         years, the LICENSOR is obliged to buy back the equipment (schedule H) bought by the
                                         LICENSEE at book value. The equipment will be depreciated by the LICENSEE in a linear
                                         way over [*]. For compensation of its investments in the contract period, the LICENSOR
                                         will pay an additional fee representing [*]% of the total license fee (this excludes
                                         the basis fee as defined in schedule A). Beyond year 5 (i.e. the initial period),
                                         the LICENSOR will pay [*]% of the latest annual license fees.

 

		10.3	Without prejudice to any claim for damages against the breaching party, either party shall be entitled
to terminate this Agreement forthwith upon giving notice to the other party if this other party commits any breach of this Agreement
and fails to remedy such breach at the end of a period of 30 (thirty) days after being given a notice containing full particulars
of the breach and requiring it to be remedied.

 

		10.4	Upon termination of this Agreement for any reason, LICENSEE shall :

 

		(a)	be entitled, for a period not exceeding a maximum of 6 months after
the date of expiry of this Agreement (“the Expiry Date”), (i) to manufacture the Product(s) to the extent necessary
to satisfy contractual obligations as given by contracts or orders with customers and accepted by LICENSEE prior to the Expiry
Date.

 

		(b)	subject to paragrph (a) above, cease forthwith (i) to use the Trademark(s) and the Product Licence(s)
and (ii) to use or otherwise exploit in any way, directly or indirectly, LICENSOR’s Know-How, except to the extent that LICENSOR’s
Know-How is, at the date of termination or at any time thereafter becomes public knowledge, otherwise than through any fault or
negligence of LICENSEE;

 

		(c)	ensure that, as soon as practically possible after termination, any reference to the Trademark(s)
and/or LICENSOR’s Logo on its premises, vehicles, business documents and advertising materials is removed and that any of
its advertisements and advertising materials containing such reference ceases to be used;

 

		10.5	After the Expiry Date, neither party shall be under any obligation to the other under this Agreement,
except that the provisions of clauses 3.5, 4, 6.3 and 11 shall continue in force in accordance with their terms, notwithstanding
termination of this Agreement.

 

Certain confidential information has been omitted from
this document, as indicated by the notation “[*]”. The omitted information has been filed on a confidential basis with
the Securities and Exchange Commission pursuant to a request for confidential treatment.

 

    	12

    	 

    

 

Furthermore the LICENSOR shall be entitled
to terminate this Agreement forthwith, by serving written notice, with immediate effect (without giving any prior notice period)
if the LICENSEE

 

		10.5.1	files a nullity suit against a contractual Property Right.

 

		10.5.2	does not achieve the agreed minimum quantities, as provided in paragraph 12.2 below;

 

		10.5.3	has lost the legal basis for pharmaceutical production, e.g. loss of production licence, GMP/certification;

 

		10.5.4	does not fullfill essential obligations of this Agreement despite a warning in writing, as provided
in paragraph 10.3 above; or

 

		10.5.5	if insolvency proceedings have been initiated against the LICENSEE assets.

 

		11.	GOVERNING LAW and SETTLEMENT OF DISPUTES

 

		11.1	This Agreement shall be governed exclusively by the substantive laws of the Republic of Austria
excluding any conflict of law provisons. This shall also apply to the ssue of the Conclusion of this Agreement as well as to the
legal consequences of its after-effet.

 

		11.2	All disputes arising out of this contract or related to its violation, termination or nullity shall
be, unless it is settled amicably within 60 (sixty) days from the date of either party’s claim against the other, finally
settled under the Rules of Arbitration and Conciliation of the International Arbitral Centre of the Austrian Federal Economic Chamber
in Vienna (Vienna Rules) by one or more arbitrators appointed in accordance with these Rules. The number of arbitrators shall be
three. The language to be used in the arbitral proceedings shall be English. The place of arbitration shall be Vienna/Austria.

 

		12.	OBLIGATION TO USE

 

		12.1.	The LICENSEE shall use its best efforts to exercise the license right, to start production without
delay and to carry out the appropriate advertising and marketing activities to promote the sales of the contracutal Product(s).

 

		12.2.	Unless the LICENSEE produces the quantities shown in Schedule E (in the line “no Batches”)
per each solar year - to be considered as minimum quantities – the LICENSOR shall be entitled to terminate this Agreement
forthwith, by serving written notice, with immediate effect (without giving any prior notice period), within [90] days after the
end of the solar year in which the relevant minimum quantities have not been achieved.

 

“It
is hereby agreed and understood that the above right of the LICENSOR to terminate this agreement shall exhaust any and all LICENSOR’s
remedies against the LICENSEE in case the latter does not reach the agreed minimum quantities and the LICENSOR shall not be entitled
to any compensation for damages.”

 

    	13

    	 

    

 

		13.	NO-CONTEST CLAUSE

 

The LICENSEE undertakes not to contest the
LICENSOR’s Know-How either by an invalidity suit, opposition or otherwise, not to assist Third Parties directly or indirectly
in contesting the LICENSOR’s Know-How. The scope of protection of this provision sall also cover the contracutal Know-How.

 

		14.	MISCELLANEOUS

 

		14.1	This Agreement and its Schedules constitute the entire agreement between the parties in relation
to the manufacture and sale of the Product(s) and the use of the Trademark(s) in the Territory and supersede all prior verbal or
written agreements between the parties, if any, relating to the same subject matter. No change to this Agreement and/or any of
its Schedules shall be binding upon the parties unless it is made in a written document signed by authorised representatives of
both parties or of their legal successors.

 

		14.2	Any notice required or permitted under this Agreement may be sent aither by certified mail, return
receipt requested, or by fax or by mail to the following addresses and numbers of the Parties:

 

If to LICENSOR:

Feldkirchnerstraße 4

A -8054 Seiersberg

Fax +43 316 28 43 00 14

Email: christoph.artner@iason.eu

 

If to LICENSEE:

20 rue Diesel

01630 Saint Genis Pouilly, France

Fax: +33-4-50 99 30 71

email: gerard.ber@adacap.com

 

		14.3	Any notice required or permitted to be given concerning this Agreement shall be effective upon
receipt by the Party to whom it is addressed as certified by the return recipt (in case of certified mail) or by confirmation of
dispatch (in case of fax) or by the massage from the adress confirming receipt (in case of email).

 

		14.4	Should any provision of this Agreement become unvalid or unenforceable under applicable laws, this
shall not invalidate or render any other provision unenforceable. The invalidated or unenforceable provision shall be deleted and
replaced, by mutual consent of both parties, by a valid or enforceable provision having an objective or similar to the objective
of the deleted provision.

 

		14.5	Neither party shall be deemed to be in breach of this Agreement, or otherwise liable to the other,
by reason of the non-performance or of any delay in the performace, of any of its obligations hereunder, to the extent that such
delay or non-performance is due to any Force Majeure, provided that the party which is so prevented from, or delayed in,

 

    	14

    	 

    

 

the performance of any of its obligations
under this Agreement shall (a) notify forthwith the other party of the occurrence and likely duration and effect of any such Force
Majeure, (b) use its best endeavours to resolve promptly or cure any matter under its own control and (c) resume performance as
soon as the Force Majeure has ceased or has been removed.

 

		14.6	Failure by either party, either permanently or temporarily, to enforce any of its rights hereunder
or to require performance by the other party of any of its obligations hereunder shall not constitute, or be deemed to constitute,
any waiver of this party’s rights under this Agreement.

 

		14.7	This Agreement is a licence agreement and nothing in this Agreement shall create, or be deemed
to create, any partnership, or any relationship of principal and agent, between the parties.

 

		14.8	Except as otherwise provided in this Agreement, each party shall bear its own costs relating to
the preparation, execution and implementation of this Agreement and all taxes relating thereto.

 

		14.9	Except with the other Party’s prior written consent, Paties shall not disclose to any third
party (except to the Authorities if required by applicable laws) or make any public announcement concerning the existence or content
of this Agreement.

 

		14.10	Both parties agree that this Agreement complies with the provisions EU Regulation 772/2004 of April
27, 2004 on technology transfer agreements and is therefore exempted from prior notification to the EU Commission.

 

Made in 2 copies, January 14,
2009

 

	LICENSOR	LICENSEE
	/s/ Christoph Artner	/s/ Gérard Ber
	Christoph Artner	Gérard Ber 
	 	for Stefano Buono

 

List of the Schedules:

 

A.: The Products

 

B.: Trade Marks

 

C.: C2 Marketing Authorization; C2 projected
Marketing Authorization

 

D.: The Terrritory; Details on Italy

 

E.: Royalties, Base Fees, After-Sales Service

 

F.: Lists of Documents according to 3.1.a

 

    	15

    	 

    

 

G.: Proposal for Labelling

 

H.: Technical Equipment

 

    	16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]